ALXN2040  Alexion Pharmaceuticals, Inc. 
Protocol ALXN2040-PNH-301 Amendment 6.3 (US) 08 Aug 2022 
Page 1 of 85 
Alexion Confidential Title Page 
Protocol Title:  A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 
Inhibitor (Eculizumab or Ravulizumab) in Patie nts with Paroxysmal No cturnal Hemoglobinuria 
Who Have Clinically Evident Extravascular Hemolysis (EVH)  
Protocol Number:  ALXN2040-PNH-301 
Compound Number:  ALXN2040 (previously ACH-0144471) 
Study Phase : 3 
Short Title:  Pi[INVESTIGATOR_736091]-on th erapy to a C5 inhibitor (eculizumab or 
ravulizumab) in patients with Paroxysmal Nocturnal Hemoglobinuria  (PNH) who have Clinically 
Evident EVH  Sponsor Name: [CONTACT_736165].  
Legal Registered Address: [ADDRESS_1005560], [LOCATION_011], MA [ZIP_CODE] [LOCATION_003] 
Regulatory Agency Identifier Number(s) Registry ID 
IND 127,[ADDRESS_1005561]  2019-003829-18 
ClinicalTrials.gov [STUDY_ID_REMOVED] 
Approval Date :  
Original Version : 18 November 2019 
Amendment 1.0 : 17 April 2020 
Amendment 2.0 : 10 June 2020 
Amendment 3.0 : [ADDRESS_1005562] 2020 
Amendment 4.0:  21 October 2020 
Amendment 5.0:  16 July 2021 
Amendment 6.0:  25 February 2022 
Amendment 6.3 (US):  08 Aug 2022  
Sponsor Signatory:  
  
 
Al
exion Pharmaceuticals, Inc.
[ADDRESS_1005563] [LOCATION_011] MA, [ZIP_CODE] [LOCATION_003] Date	




ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 2 of 85 
Alexion Confidential  Investigatorâ€™s Signature(s)  
 
Study Title:  A Phase 3 Study of Danicopan  (ALXN2040) as Add -on Therapy to a C5 
Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal 
Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular 
Hemolysis (EVH)  
 
Study Number:  ALXN2040 -PNH-301  
Version and Date Global Amendment 6.3 (US) [ADDRESS_1005564] the study as described in the protocol. 
 
 
  
 
<Name [CONTACT_2760]/Title>  
<Affiliation/Company>  
<Address>  
<Address>  
<Phone Number>  Date  
 
  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 3 of 85 
Alexion Confidential  Table of Contents  
Title Page  .........................................................................................................................................1  
Investigatorâ€™s Signature(s) ...............................................................................................................[ADDRESS_1005565] of Tables  ...................................................................................................................................6  
1. Protocol Summary ....................................................................................................................7  
1.1. Synopsis ...........................................................................................................................7  
1.2. Schedule of Assessments  ...............................................................................................17  
2. Introduction ............................................................................................................................25  
2.1. Study Rationale ..............................................................................................................25  
2.2. Background ....................................................................................................................26  
2.2.1.  Complement Factor D  ................................................................................................26  
2.2.2.  Paroxysmal Nocturnal Hemoglobinuria .....................................................................26  
2.3. Benefit/Risk Assessment  ...............................................................................................27  
2.3.1.  Meningococcal Infection ............................................................................................27  
2.3.2.  Liver Enzyme Elevations ...........................................................................................27  
2.3.3.  Coronavirus Dise ase 2019  ..........................................................................................28  
2.3.4.  Benefits  .......................................................................................................................28  
3. Objectives and Endpoints .......................................................................................................29  
4. Study Design ..........................................................................................................................32  
4.1. Overall Design  ...............................................................................................................32  
4.2. Scientific Rationale for Study Design  ...........................................................................33  
4.3. Justification for Dose .....................................................................................................34  
4.4. End of Study Definition .................................................................................................35  
4.5. Data Monitoring Committee  ..........................................................................................35  
5. Study Population ....................................................................................................................36  
5.1. Inclusion Criteria  ...........................................................................................................36  
5.2. Exclusion Criteria  ..........................................................................................................37  
5.3. Screen Failures  ...............................................................................................................38  
6. Study Drug .............................................................................................................................39  
6.1. Study Intervention Administered  ...................................................................................39  
6.2. Preparation/Handling/Storage ........................................................................................39  
6.3. Measures to Minimize Bias: Randomization and Blinding  ...........................................39  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 4 of 85 
Alexion Confidential  6.4. Assessments of Study Drug Compliance .......................................................................40  
6.5. Backgr ound and Concomitant Therapi[INVESTIGATOR_014] .......................................................................40  
6.5.1.  Background C5 Inhibitor Therapy: Eculizumab and Ravulizumab ...........................[ADDRESS_1005566] to Follow up ...........................................................................................................47  
8. Study Assessments and Procedures ........................................................................................49  
8.1. Screening Period  ............................................................................................................49  
8.2. Efficacy Assessments  ....................................................................................................50  
8.3. Patient -Reported Outcomes  ...........................................................................................50  
8.4. Safety Assessments and Procedures  ..............................................................................50  
8.4.1.  Clinical Laboratory Tests  ...........................................................................................50  
[IP_ADDRESS].  Blood Collection ................................................................................................51  
8.4.2.  Physical Examinations ...............................................................................................51  
8.4.3.  Vital Signs  ..................................................................................................................51  
8.4.4.  Electrocardiograms  .....................................................................................................51  
8.5. Adverse Events and Serious Adverse Events ................................................................52  
8.5.1.  Time Period and Frequency for Collecting AE and SAE Information ......................52  
8.5.2.  Method of Detecting AEs and SAEs ..........................................................................52  
8.5.3.  Follow-up of AEs and SAEs ......................................................................................52  
8.5.4.  Regulatory Reporting Requirements for SAEs ..........................................................52  
8.5.5.  Pregnancy  ...................................................................................................................53  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 5 of 85 
Alexion Confidential  8.6. Treatment of Overdose  ..................................................................................................53  
8.7. Pharmacokinetics  ...........................................................................................................54  
8.8. Pharmacodynamics  ........................................................................................................54  
8.9. Genetic Samples  ............................................................................................................54  
9. Statistical Considerations  .......................................................................................................55  
9.1. Statistical Hypotheses  ....................................................................................................55  
9.2. Sample Size Determination  ...........................................................................................55  
9.3. Populations for Analyses ...............................................................................................55  
9.4. Statistical Analyses  ........................................................................................................56  
9.4.1.  Patient Disposition and Demographic/Baseline Characteristics  ................................56  
9.4.2.  Study Drug Exposure, Compliance, and Concomitant and Background Therapi[INVESTIGATOR_014] ..56  
9.4.3.  Efficacy Analyses  .......................................................................................................57  
[IP_ADDRESS].  Primary Efficacy Analysis  .................................................................................57  
[IP_ADDRESS].  Secondary Efficacy Analysis .............................................................................58  
9.4.4.  Analyses of Safety  ......................................................................................................59  
9.4.5.  Analyses of Pharmacokinetics (PK) and Pharmacodynamics (PD) ...........................60  
9.5. Interim Analyses  ............................................................................................................60  
9.6. Staged Population PK/PD Analysis ...............................................................................61  
10. Supporting Documentation and Operational Considerations .................................................62  
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations........................62  
10.1.1.  Regulatory and Ethical Considerations ......................................................................62  
10.1.2.  Financial Disclosure  ...................................................................................................62  
10.1.3.  Informed Consent Process ..........................................................................................62  
10.1.4.  Data Protecti on ...........................................................................................................63  
10.1.5.  Dissemination of Clinical Study Data  ........................................................................63  
10.1.6.  Data Quality Assurance  ..............................................................................................64  
10.1.7.  Source Documents ......................................................................................................64  
10.1.8.  Study and Site Closure ...............................................................................................65  
10.1.9.  Publication Policy  .......................................................................................................65  
10.2.  Appendix 2: Clinical Laboratory Tests  ..........................................................................65  
10.3.  Appendix 3: Adverse Events: Definitions and Procedures  for Recording, Evaluating, 
Follow-up, and Reporting ..............................................................................................67  
10.3.1.  Definitions  ..................................................................................................................67  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 6 of 85 
Alexion Confidential  10.3.2.  Criteria for Assessing Seriousness .............................................................................68  
10.3.3.  Documentation and Reporting of Adverse Events .....................................................69  
10.3.4.  Treatment and Follow-Up of Adverse Events ............................................................70  
10.3.5.  Timeframe for Collection of Adverse Events ............................................................70  
10.3.6.  Severity and Grading of Adverse Events ...................................................................70  
10.3.7.  Assessment of Causality  .............................................................................................70  
10.3.8.  Pregnancy  ...................................................................................................................71  
10.3.9.  Reporting Serious Adverse Events and Pregnancies ..................................................72  
10.3.10.  Investigator Reporting Requirements for S[LOCATION_003]Rs ...........................................72  
10.3.11.  Concomitant/Background Medication Assessments .........................................72  
10.3.12.  Monitoring Participant Safety  ...........................................................................73  
10.3.13.  Removal of Participants from the Study or Study Drug ...................................73  
10.4.  Appendix 4: Contraception Guidance and Collection of Pregnancy Information .........74  
10.5.  Appendix 5: Genetics  .....................................................................................................77  
10.6.  Appendix 6: COVID -19 Risk Assessment  ....................................................................78  
10.7.  Appendix 7: COVID -19 Vaccine Risk Assessment  ......................................................80  
10.8.  Appendix 8: Abbreviations ............................................................................................[ADDRESS_1005567] of Tables  
Table 1:  Schedule of Assessment s Treatment Period 1: All Patients  ..................................17  
Table 2:  Schedule of Assessments Treatment Period 2: All Patients  ..................................20  
Table 3:  Schedule of Assessments: Long-term Extension, Taper, and Follow-up Periods .22  
Table 4:  PK and PD Blood Sampling Schedule and Approximate Volumes ......................24  
Table 5:  Study Interventions Administered .........................................................................39  
Table 6:  Study Drug Taper Schedule ...................................................................................47  
Table 7:  Protocol-Required Laboratory Assessments ..........................................................66  
Table 8:  Potential Risks and Mitigation Measures due to COVID -19.................................78  
Table 9:  Potential Risk and Mitigation Measures due to COVID -19 V accination  ..............80  
 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 7 of 85 
Alexion Confidential  1. PROTOCOL SUMMARY  
1.1.  Synopsis  
Protocol Title:  A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 
Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria 
Who Have Clinically Evident Extravascular Hemolysis (EVH)  
Short Title:  Pi[INVESTIGATOR_736091]-on therapy to a C5 inhibitor (eculizumab or 
ravulizumab) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have Clinically 
Evident EVH  
Rationale:  This is a registration study to evaluate the efficacy of danicopan as an add-on therapy 
to a C5 inhibitor (eculizumab or ravulizumab) to treat clinically -evident EVH. 
Objectives and Endpoints : 
Objectives  Endpoints  
Primary  
â€¢ To evaluate the efficacy of danicopan as 
compared to placebo as add-on therapy to 
a C5 inhibitor at 12 weeks  â€¢ Change  in hemoglobin (Hgb) relative to 
baseline after 12  weeks of treatment 
with danicopan compared to placebo 
Secondary  
Key Secondary   
â€¢ To evaluate the efficacy of danicopan on 
Hgb improvement in absence of transfusion as compared to placebo as add-on therapy to a C5 inhibitor at 12 
weeks  â€¢ Proportion of patients with Hgb increase 
of â‰¥ 2 g/dL at Week 12 in the absence of 
transfusion 
â€¢ To evaluate the efficacy of danicopan as 
compared to placebo as add-on therapy to a C5 inhibitor on transfusion avoidance at 12 weeks  â€¢ Proportion of patients with transfusion 
avoidance (TA), defined as patient s who 
remain transfusion-free and do not require a transfusion as per protocol- specified 
guidelines through Week 12 
â€¢ To evaluate the effect of danicopan as 
compared to placebo as add-on therapy to a C5 inhibitor on Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue scores at 12 weeks of treatment  â€¢ Change from baseline in FACIT Fatigue 
scores at Week  12  
â€¢ To evaluate the effect of danicopan as 
compared to placebo as add-on therapy to a C5 inhibitor on absolute reticulocyte count  â€¢ Change from bas eline in absolute 
reticulocyte count at Week  12 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 8 of 85 
Alexion Confidential  Objectives  Endpoints  
Other Secondary  
â€¢ To evaluate the efficacy of danicopan as 
add-on therapy to a C5 inhibitor on 
transfusion requirements at 24 weeks for 
those patients receiving 24 weeks of danicopan  â€¢ Change in the number of  red blood cell 
(RBC) units transfused and transfusion instances during the 24 weeks of treatment with danicopan compared to the 24 weeks prior to initiation of treatment with danicopan 
â€¢ Percentage of patients who have transfusion avoidance through 24 weeks  of 
treatment  
â€¢ To evaluate the efficacy of danicopan as 
compared to placebo as add-on therapy to a C5 inhibitor on transfusion requirements at 12 weeks  â€¢ Change in the number of RBC units 
transfused and transfusion instances during the 12 weeks of treatment with danicopan compared to the 12 weeks while receiving placebo  
â€¢ To evaluate the effect of danicopan as 
add-on therapy to a C5 inhibitor on 
Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue scores for 24 weeks of treatment  â€¢ Change from baseline in FACIT Fatigue 
scores at Week 24 in all patients  
â€¢ To assess the efficacy of danicopan as 
add-on therapy to a C5 inhibitor on Hgb 
stabilization  â€¢ Percentage of patients with Hgb 
stabilization during the last 12 weeks of treatment in patients receiving 24 weeks of danicopan 
â€¢ To evaluate the efficacy of danicopan on 
Hgb improvement in absence of transfusion as add-on therapy to a C5 inhibitor at 24 weeks â€¢ Proportion of patients with Hgb increase 
of â‰¥ 2 g/dL at Week 24 in the absence of transfusion 
â€¢ To assess additional laboratory markers 
relevant in PNH patients  â€¢ Change from baseline of danicopan  treated 
patients compared to placebo in total and direct bilirubin at 12 weeks 
â€¢ Changes in PNH RBC clone size and C3 fragment deposition on PNH RBCs at 12 weeks of treatment with  danicopan 
compared to placebo 
â€¢ Changes in lactate dehydrogenase (LDH) 
at 12  weeks  
â€¢ Percentage of patients with Hgb 
normalization at 12 weeks and 24 weeks  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 9 of 85 
Alexion Confidential  Objectives  Endpoints  
Exploratory  
â€¢ To assess Patient -Reported Outcomes 
(PRO) and other health-related quality of 
life (QoL) measures during 24 weeks of treatment  â€¢ Change from baseline relative to placebo 
in Three-level EuroQoL 5 dimensions (EQ-5D- 3L) scores at Week  12 
â€¢ Change from baseline in EQ-5D- 3L scores 
at Week 24  
â€¢ Change from baseline relative to placebo in European Organization for Research and Treatment of Can cer (EORTC) 
Quality of Life Questionnaire -Core 30 
Scale (QLQ -C30) at Week  12 
â€¢ Change from baseline in EORTC- QLQ-
C30 scale at Week  24 
â€¢ Change from baseline relative to placebo in Work Productivity and Activity Impairment Questionnaire: Anemic Symptoms (WPAI:A NS) at Week  12 
â€¢ Change from baseline in WPAI:ANS scores at Week  24 
â€¢ Change from baseline relative to placebo 
in Healthcare Resource Utilization (HRU) 
at Week  12 
â€¢ Change from baseline in HRU scores at Week  24 
â€¢ To characterize pharmacokinetics (PK) 
and pharmacodynamics (PD) of 
danicopan â€¢ Plasma concentrations of danicopan over 
time 
â€¢ Changes from baseline in PD biomarkers  
Safety  
â€¢ To evaluate the safety and tolerability of 
24 weeks of treatment with danicopan as 
add-on therapy to a C5 inhibitor  â€¢ Incidence of treatment -emergent adverse 
events (TEAEs), serious adverse events (SAEs), laboratory abnormalities, and events leading to discontinuation of study drug during Treatment Periods 1 and 2. 
â€¢ To evaluate the safety and tolerability of 
danicopan as add-on therapy to a C5 inhibitor during the long-term extension (LTE) Period  â€¢ Incidence of treatment -emergent adverse 
events (TEAEs), serious adverse events (SAEs), laboratory abnormalities, and events leading to discontinuation of study drug 
 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 10 of 85 
Alexion Confidential  Overall Design : This is a multiple -region, randomized, double-blind, placebo controlled, 
multiple -dose, Phase [ADDRESS_1005568] clinically evident EVH on a C5 
inhibitor (eculizumab or ravulizumab). This study will include approximately 84 patients who 
are receiving C5 inhibitor therapy according to the usual dose and schedule and continue to 
experience anemia with or without the need of transfusion support. At randomization, patients 
will be stratified by [CONTACT_736118] (ie, > 2 or â‰¤  2 transfusions within 6 months of Screening) 
and Hgb (ie, < 8.5 g/dL and â‰¥  8.5 g/dL) at Screening, and Japanese patients (defined as patients 
enrolled from Japan)/non- Japanese patients.  
Patients will be randomized to danicopan tid or placebo tid in a 2:1 ratio for 12 weeks (Treatment Period 1) in addition to their C5 inhibitor therapy (eculizumab or ravulizumab). At 
Week 12, patients randomized to rec eive placebo will be switched to danicopan for an additional 
12 weeks (Treatment Period 2) and patients randomized to danicopan will continue on danicopan 
for an additional 12 weeks, while remaining on the ongoing C5 inhibitor therapy. At the end of 
the tr eatment periods (Week 24), patients may enter the Long-Term Extension (LTE) Period and 
continue to receive danicopan + their C5 inhibitor therapy. 
In this study, patients will have been on a C5 inhibitor therapy for a time period sufficient to 
receive the full benefit of the therapy but still remain anemic. Prolonged therapy with a C5 
inhibitor alone is not projected to have additional impact on their clinical response. Historical transfusion needs and pretransfusion hemoglobin levels will be captured for the [ADDRESS_1005569] at any of the protocol- specified time points (Weeks 
6, 12, and 18). All dose escalations will be made on a patient-by- patient basis at the d iscretion of 
the Principal Investigator, in consultation with the Sponsor based on the protocol dose escalation guidelines (see Section 6.6). Patients  may not switch from their Day [ADDRESS_1005570] 24 weeks of the study but may do so during the LTE Period. The only authorized switch is from eculizumab to ravulizumab. 
The C5 inhibitor + placebo group will be dose- escalated in the same manner as the C5 inhibitor 
+ danicopan group during the study to maintain the blind.  After Week 12, the C5 inhibitor + placebo group will switch from placebo to receive danicopan 
during T reatment Period 2.  
All patients will return to the clinic for protocol specified assessments during the treatment periods and during the LTE Period as shown in Table 1 to Table 3. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005571] some selected visits in -clinic or via the home healthcare 
service provided by [CONTACT_1034]. With this service, the patient does not physically visit the 
investigative site. Instead, a healthcare provider visits the patient at the patientâ€™s residence to perform protocol- specified assessments.  
Upon completion of Treatment Period 2 (Week 24), pat ients may enter the LTE Period at the 
same danicopan dose they were receiving at Week 24, plus their C5 inhibitor therapy. During the LTE Period, patients may be dose escalated, to a maximum of [ADDRESS_1005572] year of LTE (Year 1) and a second year of optional LTE (Year 2). All patients will complete 72 weeks of LTE (Year 1) assessments as shown in Tab le 3. 
After Week 72 (at the end of the first year of LTE), patients have the choice to complete participation in this study or continue to the optional second year of LTE. Once Study ALXN20 40PNH-[ADDRESS_1005573] transition without treatment interruption to Alexion study ALXN2040- PNH-303, 
completing the End of Treatment Period Visit as soon as possible (no taper or follow up visits are required), or complete participation in the current study by [CONTACT_736119], plus Taper and Follow Up Visits as soon as possible. See Section 4.4 for definition 
of study completion. 
If a patient discontinues from the study, dosing of danicopan or placebo should be tapered over 
6 days (Taper Visit 1 and 2), and a Follow-up Visit will be conducted approximately [ADDRESS_1005574] dose of study drug. Patients will continue to receive their C5 inhibitor therapy at the same dose and interval that they were receiving during the taper and follow-up visits. 
Number of Patients:  Approximately 84 patients on a C5 inhibitor will be enrolled and treated 
with danicopan or placebo (2:1 ratio).  
Intervention Groups and Duration:  Patients will be randomized to danicopan or placebo, in a 
2:1 ratio, for 12 weeks (Treatment Period 1) in addition to their C5 inhibitor therapy. At 
Week  12, patients randomized to receive placebo will be switched to danicopan for an additional 
12 weeks (Treatment Period 2), and patients randomized to danicopan will continue for an 
additional 12 weeks. At the end of the treatment periods (24 weeks), patients may enter the LTE 
Period at the same dose plus their C5 inhibitor therapy. Any patient discontinuing from the study at any time point should undergo a 6-day taper and will have a Follow- Up Visit approximately 
[ADDRESS_1005575] dose during the Tapering Period. 
The C5 inhibitor (eculizumab or ravulizumab) used in this study will be considered a background 
therapy. If patients switch from eculizumab to ravulizumab after completion of 24 weeks of treatment, the new medication used in this manner will also be considered a background therapy. 
Inclusion Criteria:  
1. Diagnosis of PNH  
2. Clinically evident extravascular hemolysis (EVH) define d by: 
â€¢ Anemia (Hgb â‰¤  9.5 g/dL) with absolute reticulocyte count â‰¥  120 Ã— 10
9/L. 
3. Receiving an approved C5 inhibitor for at least 6 months prior to Day 1 in this study at 
an approved dose (or higher) and with no change in the prescribed dose or interval for 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005576] the loading dose and 3 
maintenance doses (minimum of 24 weeks) of ravulizumab preceding Day 1. Infusions outside the prescribed interval due to logistical reasons/patient convenience are not 
considered a change in the prescribed frequency and should be discussed with the 
Medical Monitor prior to randomization. 
4. Platelet count â‰¥  30,000/ÂµL without the need for platelet transfusions. 
5. Absolute neutrophil counts â‰¥  500/Î¼L.  
6. Documentation of vaccination for Neisseria meningitidis : All patients must be 
vaccinated against meningococcal infections within [ADDRESS_1005577] receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. 
7. Age 18 years or older (or greater than or equal to minimum adult age in accordance with local legal requirements).  
8. Female patients of childbearing potential must agree to use a highly effective or 
acceptable method of contraception from the date of signing the informed consent until 
the specified duration after the last dose of their background C5 inhibitor as per the product labelling. Female patients of childbearing potential must also have a negative serum pregnancy test during Screening and negative urine pregnancy test on Day 1. 
9. Female patients with documented evidence of non-childbearing potential need not employ a method of contraception. 
10. Nonsterile male patients must agree to use a highly effective or acceptable method of contraception with their partner(s) of childbearing potential from the first day of dosing to [ADDRESS_1005578] dose of study drug. 
â€¢ Males who are surgically sterile need not employ additional contraception. 
â€¢ Males must agree not to donate sperm while enrolled in this study and for [ADDRESS_1005579] 30 days prior to Day 1. See Section 6.5.  
Exclusion Criteria:  
1. History of a major organ transplant (eg, heart, lung, kidney, liver) or hematopoietic stem cell transplantation (HSCT).  
2. Known aplastic anemia or other bone marrow failure that requires HSCT or other 
therapi[INVESTIGATOR_247849]-thymocyte globulin and/or immunosuppressants, unless the 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005580] 12 weeks before Day 1 
and patient is expected to remain on stable doses through Week 24 (see Section 6.5).  
3. Received another investigational agent other than C5 inhibitors (eculizumab or ravulizumab) within 30 days or 5 half-lives of the investigational agent prior to study entry, whichever is greater.  
4. Known or suspected complement deficiency.  
5. Known underlying bleeding disorders (eg, coagulation factor deficiencies, idiopathic 
thrombocytopenic purpura, Von Willebrand disease, etc.) or any conditions leading to 
anemia that are not primarily due to PNH.  
6. Active bacterial or viral infection, a body temperature >38Â°C on two consecutive daily 
measures, evidence of other infection, or history of any febrile illness within [ADDRESS_1005581] study drug administration. 
7. History or presence of any clinically relevant co -morbidities that would make the patient 
inappropriate for the study (e.g., is likely to result in deterioration of the patientâ€™s condition, affect the patientâ€™s safety during the study, or confound the results of the study). 
8. Laboratory abnormalities at screening, including: 
â€¢ Alanine aminotransferase (ALT) > 2 Ã— ULN (> 3 Ã— ULN in the case of patients with 
documented liver iron overload defined by [CONTACT_736120] â‰¥ 500 ng/mL). The inclusion of patients with documented iron overload and ALT > 2 Ã— ULN will be done in a case by [CONTACT_413], with prior discussion with the Medical Monitor. 
â€¢ Direct bilirubin >  2 Ã— ULN, with the exception of: 
o patients who, in the opi[INVESTIGATOR_8925], have direct bilirubin > 2 Ã— ULN due to EVH and/or  
o patients with documented Gilbertâ€™s syndrome (if Gilbert's syndrome is suspected, the patient will be tested for this condition at screening).  
9. Any other clinically significant laboratory abnormality as judged by [CONTACT_49229], in the opi[INVESTIGATOR_1237], would make the patient inappropriate for the study or put the patient at undue risk. 
10. Females who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration. 
11. Current evidence of biliary cholestasis. 
12.  Evidence of hepatitis B (positive hepatitis surface antigen [HBsAg] or positive core antibody [anti-HBc] with negative surface antibody [anti- HBs]) or hepatitis C viral 
infection (HCV antibody positive), except for patients with documented successful treatment and documented sustained virologic response (SVR) at Screening. 
13.  Evidence of human immunodeficiency virus (HIV antibody positive) infection at Screening . 
14. Estimated glomerular filtration rate <  30 mL/min/1.73  m
2 and/or are on dialysis. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 14 of 85 
Alexion Confidential  15. Hypersensitivity to the investigational drug (danicopan) or any of its excipi[INVESTIGATOR_736092] (DMC):  
An independent DMC comprising experts in relevant biomedical fields and one external 
statistician who have no direct relationship with the study will be appointed by [CONTACT_456]. The 
DMC will review and evaluate the accumulated study data for patient safet y and make 
recommendations on continuing study drug administration. The DMC will review study 
information on a regular basis as outlined in the DMC charter, which is maintained separately 
from the study protocol. Final decisions regarding the conduct of the study will be made by [CONTACT_736121]. All appropriate regulatory authorities and IRBs/IECs will be notified of any significant action.  
Statistical Methods:  
The null statistical hypothesis is the improvement in hemoglobin le vels from baseline at 
Week  12 for danicopan treatment being similar to the improvement for placebo treatment; that is, 
the difference in mean changes from baseline between danicopan and placebo at Week 12 is 
zero.  
Sample Size Determination : 
The PNH literat ure indicates that patients with PNH who have received a C5 inhibitor 
(eculizumab or ravulizumab) but are still anemic have hemoglobin levels, on the average, of 10.5 g/dL. All patients entering this study will have a hemoglobin level of â‰¤  9.5 g/dL. A 
minimum of 2 g/dL in difference between danicopan and placebo treatments in terms of mean improvement from baseline after 12 weeks of treatment is considered clinically meaningful. 
A total of approximately 84 patients will be enrolled into this study to ensure an evaluable 
number of patients in each study arm. It is anticipated that approximately 10% of patients will 
discontinue prior to the primary endpoint. For the primary endpoint of change from baseline to Week [ADDRESS_1005582] is 99% to detect the 
difference in mean change from baseline of 2 g/dL (alternative hypothesis), assuming the statistical significance level of 0.05 (two -sided) and the standard deviation of 1.6 g/dL which is 
estimated from study ACH471 -101. For the key secondary endpoint of patients with Hgb 
increase of â‰¥ 2 g/dL at Week 12 in the absence of transfusions, the study has >95% power assuming at least 35% of patients in the danicopan arm and 5% of patients in the placebo arm can meet t he criterion.  
For the key secondary endpoint of patients with transfusion avoidance (TA), the study has70% power for the TA endpoint, assuming 90% of patients in the danicopan arm and 64% of patients in the placebo arm will have TA. For the key secondary endpoint of change from baseline to 
Week 12 in FACIT-Fatigue score, the study has 91% power with two- sample t -test to detect a [ADDRESS_1005583] deviation 
of 11 for the FACIT-Fatigue change, which was observed in Study ALXN1210- PNH-301 in 
PNH patients. The power is 80% based on the standard deviation assumption of 13, which was 
observed in Study ACH471-101. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 15 of 85 
Alexion Confidential  Analysis populations are as follows: 
â€¢ Intent- to-treat (ITT) population: All randomized patients; data will be analyzed by [CONTACT_736122], even if the patient does not 
take the assigned treatment, does not receive the correct treatment, or does not 
comply with the protocol.  
â€¢ Per Protocol population: Intent- to-treat (ITT) patients who do not have protocol 
deviations expected to affect the primary efficacy endpoint (Week 12). Such protocol deviations will be  prespecified in the statistical analysis plan prior to database lock.  
â€¢ Safety population: All patients who take at least one dose of study drug. 
If the ITT population and Per Protocol population have a similar number of patients (<5% difference), analyses will not be performed using the Per Protocol population. 
Efficacy Analyses:  Summary statistics for the baseline and post- baseline measurements, and 
changes from baseline will be presented by [CONTACT_736123].  
The p rimary efficacy endpoint is the change in hemoglobin at Week 12 relative to baseline 
(defined as the lowest Hgb value, between and including screening and Day 1) between danicopan and placebo. The longitudinal changes from baseline in hemoglobin will be analyzed using a mixed model for repeated measures (MMRM) ( Mallinckrodt, 2001,  
Mallinckrodt, 2004) which includes the fixed, categorical effects of treatment, study visit, and study visit by [CONTACT_65096], fixed covariate of baseline hemoglobin value and the stratification randomization indicator of transfusion history in the 
model. The Kenward-Roger approximation will be used to estimate denominator degrees of 
freedom. The primary test for statistical significance of the treatment group difference between the danicopan and placebo arms at Week [ADDRESS_1005584] procedure to determine the statistical significance at a level of 0.05 for each endpoint sequentially. 
Safety Analyses:  All safety analyses will be conducted on the Safety population. The evaluation 
of safety will be performed separately for the 12- week blinded Treatment Period  1, subsequent 
12-week Treatment Period 2 , and the LTE Period. The safety analysis will be based primarily on 
the frequency of adverse events, clinical laboratory assessments, vital signs, and 12- lead 
electrocardiogram (ECG). Other safety data will be summarized as appropriate.  
Descriptive statistics using summary statistics will be calculated for quantitative safety data as 
well as for the difference to baseline by [CONTACT_765], when appropriate. No inferential statistical analysis 
of safety data is planned. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 16 of 85 
Alexion Confidential  Interim Analysis: An interim analysis may be conducted at the discretion of the study sponsor 
(based on enrollment progression) when approximately 75% of patients have been randomly 
assigned to study treatment and have had the opportunity to complete the 12- week Treatment 
Period 1 (information fraction = 0.75). The purpose of the interim analysis is to evaluate the 
study for stoppi[INVESTIGATOR_681807]. If conducted, the primary endpoint of change in Hgb levels 
at Week  12, as well as the key secondary endpoints will be evaluated using the alpha-spending 
methods specified below to control family- wise error rate.  
â€¢ The evaluation of primary endpoint at interim analysis will be using the gamma family alpha -spending function ( Hwang, 1990) with parameter -4.  
â€¢ The evaluation of key secondary endpoints at interim analysis will be using the gamma family alpha -spending function with parameter 1. 
Due to the hierarchical nature of primary and key secondary endpoint, and proper alpha-spending function used to control error rate at one -sided 0.025 level for each endpoint, the overall family-
wise error rate is controlled at one-sided 0.025 level across primary and key secondary endpoints among interim and final analyses ( Glimm, 2010, Tamhane, 2010). The recommendation of 
stoppi[INVESTIGATOR_736093]-controlled Treatment Period 1 for efficacy can be made 
only if, at a minimum, the primary endpoint and the key secondary endpoints of proportion of 
patients with Hgb increase â‰¥ 2g/dL in the absence of transfusion and proportion of patients with transfusion avoidance through the 12week Treatment Period 1 meet the prespecified significance level. .  
The interim analysis will be conducted under the auspi[INVESTIGATOR_736094]. The final decision to stop the study enrolment and placebo-controlled Treatment Period 1 for efficacy will 
be done by [CONTACT_736124]. The DMC revi ew of the data will 
be independent of the Sponsor as the Sponsor will remain blinded. Details of the DMCâ€™s 
responsibilities and logistics will be outlined in the charter before the dosing of the first patient.  
 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 17 of 85 
Alexion Confidential  
 1.2. Schedule of Assessments  
Table 1: Schedule of A ssessments Treatment Period 1: All Patients  
 Screening  Treatment Period 1  
 Day -45  
to -1 Day 1  Wk 1  Wk 2  Wk 3  Wk 4  Wk 6  Wk 76 Wk 8  Wk 10  Wk 12  
Clinic visit days1 X X  X  X X  X  X 
Visiting healthcare assessment2   X  X   X  X  
N. meningitidis  vaccinations3 X Administer according to local/national guidelines  
Study drug dispensing4  X    X X  X  X 
Drug accountability     X  X X  X  X 
Dose escalation decision day5       X    X 
CLINICAL ASSESSMENTS             
Informed consent  X           
Inclusion/exclusion criteria  X X          
Randomization   X          
Review safety card   X X X X X X X X X X 
Medical history  X X          
Demographics  X           
Vaccination history  X           
Height  X           
Physical exam7 X X  X  X   X  X 
Vital signs  X X  X  X   X  X 
Weight  X X  X  X   X  X 
12-lead ECG (single)   X         X 
PRO and QoL questionnaires8  X  X  X   X  X 
RBC transfusion review  X X  X  X   X  X 
AE/SAE  X X X X X X X X X X X 
Concomitant medications/ protocol 
restrictions  X X X X X X X X X X X 
FSH9 X           
HCV, HBs Ag, HIV  X           
Erythropoietin  X           
Sample for genetic testing (optional, 
white blood cells)   X          
Hematology, chemistry, and urinalysis10 X X X X X X5 X X X X X14 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 18 of 85 
Alexion Confidential  
 Table 1: Schedule of A ssessments Treatment Period 1: All Patients  
 Screening  Treatment Period 1  
 Day -45  
to -1 Day 1  Wk 1  Wk 2  Wk 3  Wk 4  Wk 6  Wk 76 Wk 8  Wk 10  Wk 12  
Pregnancy test11 X X  X  X   X  X 
PT/PTT/INR, D -dimer  X     X     X 
Free hemoglobin, haptoglobin   X  X  X   X  X 
Iron studies12 X          X 
Direct Coombs  X X    X     X 
Flow cytometry: clone size   X    X     X 
Flow cytometry: C3  fragment 
deposition   X    X     X 
Bb, AP activity, FD, C3, CP activity, 
free C513  X    X     X 
PK samples13  X    X     X 
Abbreviations: AE = adverse event; AP = alternative pathway; Bb = Bb fragment of complement factor B; C3 = complement protein  3; C5  = complement protein 
5; CP = classical pathway; ECG = electrocardiogram; ET = early termination; FD = factor D; FSH = follicle -stimulating hormone; Hgb = hemoglobin; Hbs Ag 
= hepatitis B surface antigen; HCV = hepatitis C virus; HIV= human immunodeficiency virus; HRU  = Healthcare Resource Utilization; INR = international 
normalized ratio; PD = pharmacodynamics; PK= pharmacokine tics; PRO  = patient- reported outcome; PT  = prothrombin time; PTT = partial thromboplastin 
time; QoL = quality of life; RBC = red blood cell; SAE = serious adverse event.; Wk = week.  
1 Visit window is  Â± 1 day for Weeks 1 through 12. A patient can discontinue from the study at any time and should complete all Week 24/ET assessments at final 
visit.  
[ADDRESS_1005585] until their next appointment. On the vis its where PK/PD sampling will be done, the site will instruct 
the patient to take their study drug dose at the clinic. For in- clinic dosing, the kit dispensed at the corresponding visit (not the kit being returned from the 
previous visit) should be used. At dose escalation visits, patients will return to the clinic to be dispensed study drug and receive new dosing instructions.  
5 Weeks 6 and 12 are potential dose escalation time points. Hgb at Weeks 4 and 10 are to be used for dose escalation decisions at Weeks 6 and 12, respectively 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 19 of 85 
Alexion Confidential  
 Table 1: Schedule of Assessments Treatment Period 1: All Patients  
[ADDRESS_1005586] 2 doses prior to the in- clinic dose, and the missing doses (morning, noon, or evening) in the last 2 days. Site will obtain a predose 
sample and a 2  Â± 0.[ADDRESS_1005587] dose PK sample. Samples for AP activity, Bb, FD, C3, CP activity, and free C5 should be taken at the same time as the PK 
samples (pre and post dose, as needed). Actual sampling time and the most recent dose time prior to sample collection should be recorded. See Table  [ADDRESS_1005588] be obtained at the Week 12 visit for all patients.  
 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 20 of 85 
Alexion Confidential  
 Table 2: Schedule of Assessments Treatment Period 2: All Patients  
 Wk 13  Wk 14  Wk 15  Wk 16  Wk 18  Wk 196 Wk 20  Wk 22  Wk 24/ET11 
Clinic visit days1  X  X X  X  X 
Visiting healthcare assessement2 X  X   X  X  
N. meningitidis  vaccinations3 Administer according to local/national guidelines  
Study drug dispensing4    X X  X  X 
Drug accountability   X  X X  X  X 
Dose escalation decision5     X     
Review safety card  X X X X X X X X X 
Brief Physical exam   X  X   X  X 
Vital signs   X  X   X  X 
Weight   X  X   X  X 
12-lead ECG (single)          X 
PRO and QoL questionnaires7  X  X   X  X 
RBC transfusion review   X  X   X  X 
AE/SAE  X X X X X X X X X 
Concomitant medications/ protocol 
restrictions  X X X X X X X X X 
Hematology, chemistry, and 
urinalysis8 X X X X X X X X X12 
Pregnancy test9  X     X  X 
PT/PTT/INR, D -dimer     X     X 
Free hemoglobin, haptoglobin   X  X   X  X 
Iron studies          X 
Direct Coombs     X     X 
Flow cytometry: clone size     X     X 
Flow cytometry: C3  fragment 
deposition     X     X 
Bb, AP activity, FD, C3, CP 
activity, free C510    X     X 
PK samples10    X     X 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 21 of 85 
Alexion Confidential  
 Table 2: Schedule of Assessments Treatment Period 2: All Patients  
Abbreviations: AE = adverse event; AP = alternative pathway; Bb = Bb fragment of complement factor B; C3 = complement protein  3; C5 = complement protein 
5; CP = classical pathway; ECG  = electrocardiogram; EORTC QLQ30 = European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire -Core 30 Scale; ET= early termination; FD = factor D; Hgb  = hemoglobin; HRU  = Healthcare Resource Utilization; INR = international 
normalized ratio; PK= pharmacokinetics; PRO  = patient- reported outcome; PT  = prothrombin time; PTT = partial thromboplastin time; QoL = quality of life; 
RBC = red blood cell; SAE = serious adverse event; Wk = week; WPAI:ANS = Work Productivity and Activity Impairment Questionna ire: Anemic 
Symptoms.  
1 Visit window is  Â± [ADDRESS_1005589] until their next appointment. At dose escalation visits, patients will return to the clinic to be dispensed study drug and receive new dosing instructions.  
5 Week 18 is a potential dose escalation time point. Hgb at Week 16 is to be used for d ose escalation decision at Week  18. 
6 Week 19 is applicable only for patients who are dose escalated. If a dose escalation occurs, blood will be drawn for safety l aboratory assessments by [CONTACT_736125] 1  week after escalati on. 
7 PROs and QoLs should be performed as early as possible during clinic visits. If patient is to receive infusion of their C5 inhibitor agent on a clinic visit where PROs and QoLs will be obtained, it is recommended that patients fill the PROs and QoL instruments before the C5 inhibitor infusion. Refer to PRO and QoL questionnaires in Section 8.3. Healthcare Resource Utilization (HRU), EORTC -QLQ30, and WPAI:ANS will be collected only at Week  24. 
[ADDRESS_1005590] 2 doses prior to the in- clinic dose, and the missing doses (morning, noon, or evening) in the last 2 days. Site will obtain a predose 
sample and a 2  Â± 0.[ADDRESS_1005591] dose PK sample. Samples for AP activity, Bb, FD, C3, CP activi ty, and free C5 should be taken at the same time as the PK 
samples (pre -and postdose, as needed). Actual sampling time and the most recent dose time prior to sample collection should be recorded. S ee Table  [ADDRESS_1005592] be obtained at the Week 24 visit for all patients . 
 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 22 of 85 
Alexion Confidential  
 Table 3: Schedule of Assessments: Long -term Extension, Taper, and Follow- up Periods  
 Long -term Extension 
Year [ADDRESS_1005593]-
escalation 
Visit2 End of 
Treatment 
Period Visit / 
Wk 72 or 1201 
/ ET Taper4 Follow Up 
 VHA Visits2 Clinic 
Visits3 VHA 
Visits2 Clinic 
Visits2 
 Weeks 28, 
36, 44, 52, 
60, 68  Weeks 
32,40, 48, 
56, 64  Weeks 80, 
96, 112  Weeks 88, 
104   T1 
Taper 
Days 1 -3 T2 
Taper Days 
4-6 F/U10 
Clinic visit days   X  X  X   X 
Visiting healthcare 
assessment  X  X    X X  
N. meningitidis  
vaccinations  Administer according to local/national guidelines  
Study drug dispensing5  X  X  X    
Drug accountability   X  X  X X X X 
Review safety card X X X X X X X X X 
Brief physical exam   X  X  X   X 
Vital signs   X  X  X   X 
Weight   X  X  X   X 
PRO and QoL 
questionnaires6  X  X  X    
RBC transfusion review   X  X  X   X 
AE/SAE  X X X X X X X X X 
Concomitant medications/ 
protocol restrictions  X X X X X X X X X 
Hematology, chemistry, 
and urinalysis7 X X X X X X    
Pregnancy test8 X X X X  X   X 
PT/PTT/INR, D -dimer   X  X  X    
Free hemoglobin, 
haptoglobin   X    X    
Direct Coombs   X    X    
Flow cytometry: clone 
size9  X    X    
Flow cytometry: 
C3 fragment deposition9  X    X    
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 23 of 85 
Alexion Confidential  
 Table 3: Schedule of Assessments: Long -term Extension, Taper, and Follow- up Periods  
Abbreviations: AE = adverse event; C3 = complement protein 3; EOS = end of study; ET = early termination; F/U = follow -up; INR  = international normalized 
ratio; LTE  = long term extension; PRO  = patient- reported outcome; PT= prothrombin time; PTT  = partial thromboplastin time; QoL = quality of life; RBC = 
red blood cell; SAE  = serious adverse event ; T = taper; VHA  = visiting healthcare assessment.  
1 Week 72 and Week 120 visit window is Â± [ADDRESS_1005594] year of LTE (Year 1) and a second year of optional LTE (Year 2). All 
patients will complete 72 weeks of LTE (Year 1) as sessments. After Week 72 (at the end of the first year of LTE), patients have the choice to complete 
participation in this study or continue to the optional second year of LTE. Once Study ALXN2040PNH -[ADDRESS_1005595] transition without treatment interruption to Alexion study ALXN2040- PNH -303, completing the end of treatment period 
visit as soon as possible (no taper or follow up visits are required), or complete participation in the current study by [CONTACT_736126], plus taper and follow up visits as soon as possible. See Section 4.4 for definition of study completion.  
2 VHA visit window is Â± [ADDRESS_1005596] been assessed. If needed, site may ask about AEs, SAEs, and concomitant  medications over the phone.  
3  Visit window is Â± 4 days. If a dose escalation occurs, blood should be drawn for safety laboratory assessments by [CONTACT_736127] 
72 to 96 hours after escalation.  
4 Any patient who discontinues study drug will complete Taper and Follow -up Periods. T1 and T2 may be done through VHA or via phone call on Day 3 and 
Day 6 of the Taper Period. If a patient discontinues from the study for any reason, all early termination patients should follow Week 24/ET Visit assessments. 
See Section 7.[ADDRESS_1005597]. 
9 Tests will be performed at Weeks 40, 56, 72 and Weeks 88, 104, and 120, if applicable.  
10 F/U: Clinic visit 30 (+ 7) days after the last dose of the study drug. Patients will be instructed to bring back all remaining study drugs on this visit . See 
Section  7.2. 
  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 24 of 85 
Alexion Confidential  
 Table 4: PK and PD Blood Sampling Schedule and Approximate Volumes  
Test Blood Collection on  
Day 1  
Volume (mL)1 Blood Collection on Other 
Scheduled Visits Week 4, 
Week 12, Week 16, Week 24 
(mL)1 Matrix Types  
PK 2 mL predose  
2 mL postdose  2 mL predose  
2 mL postdose  Plasma  
AP activity  1 mL predose  
1 mL postdose  1 mL predose  
1 mL postdose  Serum  
FD 2 mL predose  2 mL predose  Plasma  
Bb 2 mL predose  
2 mL postdose  2 mL predose  Plasma  
C3 1 mL predose  1 mL predose  Serum  
CP activity  1 mL  predose  1 mL predose  Serum  
Free C5  1 mL  predose  1 mL predose  Serum  
Volume  15 mL  13 mL * 4 visits = 52 mL   
Total volume  67 mL2 
Predose = immediately prior to in -clinic dose administration; postdose = 2  Â± 0.5 h after in -clinic dose administration   
Abbreviations: AP = alternative pathway; Bb = Bb fragment of complement factor B;  C3 = complement protein 3; 
C5 = complement protein 5; CP= classical pathway; FD  = factor D; PD = pharmacodynamics; PK = 
pharmacokinetics.  
1 During PK/PD sampling visits, patients are instructed to bring their study drug to the clinic. Patients should have a 
snack and take their dose of study drug in the clinic [ADDRESS_1005598] 2 doses prior to the in- clinic dose, and the missing doses 
(morning, noon, or evening) in the last 2 days. Site will obtain a predose sample and a 2 Â± 0.5 hours postdose PK 
sample. PD samples should be taken at the same time as the PK samples (pre- and postdose). Actual sampling time 
and the most recent dose time prior to sample collection should be recorded.  
2 Volumes may slightly vary dependi ng on site and laboratory specifications. Details are provided in the study 
laboratory manual.  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 25 of 85 
Alexion Confidential  
 2. INTRODUCTION 
Danicopan (ALXN2040, previously ACH-0144471), a small molecule, orally administered, 
factor D (FD) inhibitor, is being developed for the treatment of complement -mediated diseases, 
such as paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G). Factor D is 
a serine protease that catalyzes the cleavage of factor B (FB), a rate -limiting step in the 
alternative pathway (AP) of complement. By [CONTACT_736128], danicopan potently and specifically inhibits AP activity.  
Interim data from a Phase 2 proof- of-concept study (ACH471-101) has demonstrated the 
efficacy of danicopan, in addition to eculizumab, a C5 inhibitor, at stable dose and regimen, to increase hemoglobin levels after 24 weeks of treatment in PNH patients. Results from this ongoing Phase 2 combination study demonstrates clinically significant improvements in both the 
primary and secondary endpoints. A mean increase in hemoglobin â‰¥ 2 g/ dL was demonstrated, 
from a baseline mean of 7.9 g/dL. The efficacy was observed as early as Week [ADDRESS_1005599] clinically 
evident extravascular hemolysis (EVH) on a C5 inhibitor (eculizumab or ravulizumab). 
A detailed description of the chemistry, pharmacology, efficacy, and safety of danicopan is 
provided in the Investigatorâ€™s Brochure. 
2.1. Study Rationale  
This study is a pi[INVESTIGATOR_736095] C5 inhibitor.  
C3 fragment deposition on PNH red blood cells (RBCs) during C5 inhibitor treatment is a likely 
cause for suboptimal response due to extravascular clearance of PNH RBCs coated by C3 
fragments ( Risitano, 2009) . Danicopan inhibits the complement cascade upstream of C3 and also 
blocks the complement amplification loop. Danicopan has been shown to prevent deposition of 
C3 fragments on PNH erythrocytes ex vivo  (Yuan, 2017). As a result, both intravascular 
hemolysis (mediated by [CONTACT_736129]) and extravascular 
hemolysis (EVH, likely via C3 fragment opsonization) could be blocked or significantly 
attenuated by [CONTACT_736130]. In addition, although danicopan does not inhibit components specific to 
the classical or lectin complement pathways, nor does it inhibit components of the terminal 
complement pathway, it will inhibit the AP -mediated amplification of complement activity 
initiated via the classical and lectin pathways. Lastly, FD is among the lowest plasma concentrations of all complement plasma proteins, making it a more druggable target. 
Currently approved treatments for PNH are the humanized monoclonal antibodies C5 inhibitors 
eculizumab (SolirisÂ®) and ravulizumab (UltomirisÂ®). In countries where these products are 
authorized, eculizumab and ravulizumab will be used in this study as commercial background therapi[INVESTIGATOR_014]. However, the ultimate intent and scope of this study is to evaluate the benefit/risk of danicopan as add-on therapy to C5 inhibitors in PNH patients. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005600] 
abundance in serum with a concentration of approximately 2 Âµg/mL ( Schnabolk, 2015), and is 
the rate- limiting step of AP activation ( Figueroa, 1991, Volanakis, 1996) . It is a low molecular 
weight protein (24 kDa) that is primarily produced by [CONTACT_736131]/macrophages and astrocytes in humans ( Figueroa, 1991,  
Volanakis, 1996) . Due to its small size, it is freely filtered at the glomerulus, and then taken up 
by [CONTACT_736132] 60% per hour. It is this rapid catabolism that is responsible for maintaining low circulating FD levels. As a result, renal dysfunction is associated with elevated FD levels, which may lead to 
increased AP activity and inflammation ( Kobayakawa, 1992, Miyata, 1991). The biochemical, 
physiological, and functional feature s of FD make it an attractive target for pharmacological 
inhibition as this may prove useful in the treatment of a wide spectrum of complement- mediated 
diseases.  
2.2.2. Paroxysmal Nocturnal Hemoglobinuria 
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare disease that has a reported prevalence of 
approximately 16 per million people ( Hill, 2007). PNH may occur at any age; it has been 
reported in children as young as [ADDRESS_1005601] frequently diagnosed in adults, with a median age at diagnosis of approximately 40 years ( Curran, 2012, 
Hillmen, 1995) . Men and women are affected equally, and no familial tendencies exist.  
PNH is caused by a somatic mutation in the phosphatidylinositol N-acetylglucosaminyl transferase subunit A (PIG-A) gene in one or more hematopoietic stem cells, resulting in the loss of glycosylphosphatidylinositol-anchored proteins, including the complement regulatory proteins 
CD55 and CD59, from the surface of mutant RBCs. This leaves these mutant RBCs vulnerable 
to intravascular hemolysis mediated by [CONTACT_736133], presumably mediated by C3 fragment opsonization, primarily due to 
constitutive activation of the complement AP via the tick over mechanism ( Schubert, 2015) . In 
addition to anemia that can require frequent RBC transfusions, PNH patients are at high risk for thrombotic events, which can be life-threatening and is the major cause of morbidity and 
mortality in untreated patients. PNH patients also experience smooth muscle dysfunction (e.g., 
dysphagia, erectile dysfunction, abdominal pain), presumably related to the liberation of intracellular hemoglobin (Hgb) and consequent derangement of nitric oxide levels in the vasculature.  
The only curative treatment for PNH is hematopoietic stem cell transplantation (HSCT) using allogeneic donors. Given the high transplant-related morbidity and mortality, especially when 
using unrelated or mismatched donors, HSCT is generally not offered as initial therapy for most 
patients with classic PNH. Other supportive therapi[INVESTIGATOR_31430]: Recombinant erythropoietin, corticosteroids, and androgens to stimulate erythropoiesis; anticoagulants to treat thrombotic complications; and immunosuppressive agents to stimulate hematopoiesis in the aplastic phase. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 27 of 85 
Alexion Confidential  
 Currently approved treatments for PNH are the humanized monoclonal antibody C5 inhibitors 
eculizumab and ravulizumab and the C3 inhibitor pegcetacoplan. Although C5 inhibitors prevent 
intravascular hemolysis by [CONTACT_736134], approximately 30% of patients on eculizumab continue to have ongoing extravascular hemolysis ( Debureaux, 
2019). 
2.3. Benefit/Risk Assessment  
2.3.1. Meningococcal Infection  
Since a primary function of the complement system is to fight infections, pharmacologic inhibition of the complement system could theoretically result in an increased rate or severity of 
infections. As suggested by [CONTACT_736135], 
including FD, inhibition of the complement system may result in a lifetime increased risk of 
infection, notably with Neisseria meningitidis  (Biesma, 2001, Hiemstra, 1989, Sprong, 2006) . 
Patients receiving complement inhibitor therapy such as C5 inhibitors, in general, may have increased susceptibility to  increased risk of bacterial infections, particularly Neisseria 
meningitidis  (SociÃ©, 2019) . However, this risk remains theoretical for FD inhibition as the 
classical pathway of complement is not inhibited by [CONTACT_736136] (Konar, 2017 ). 
To reduce the risk of meningococcal infection, all patients must be vaccinated against meningococcal infections within [ADDRESS_1005602] be vaccinated or revaccinated according to current national vaccination guidelines 
or local practice for vaccination use with complement inhibitors (e.g., Advisory Committee on Immunization Practices ([ACIP]). Vaccination may not be sufficient to prevent meningococcal 
infection. All patients should be monitored for early signs of meningococcal infection, evaluated 
immediately if infection is suspected, and treated with appropria te antibiotics, if necessary.  
To increase risk awareness and promote quick disclosure of any potential signs or symptoms of 
infection experienced by [CONTACT_433870], patients will be provided a 
Patient Safety Card to carry with them at all times. Additional discussion and explanation of the potential risks, signs, and symptoms will occur at specific time points as part of the review of the 
Patient Safety Card and throughout the study as described in the Schedule of Assessments in 
Section  1.2. 
2.3.2. Liver Enzyme Elevations  
In human healthy volunteers, elevations in alanine aminotransferase (ALT) levels have been 
observed in the multiple ascending dose study (ACH471-002) with the high doses of 500 mg 
twice daily and 800 mg twice daily for 14 days (Investigators Brochure). These ALT elevations were not associated with signs or symptoms of hepatic failure, occurred after completion of dosing, and were self- limited.  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005603] occurred in the Phase 2 PNH studies, some in 
association with breakthrough hemolysis. These transient elevations were not associated with 
evidence of hepatic decompensation and resolved within a short time period. Liver function tests including, ALT, aspartate aminotransferase (AST), alkaline phosphatase (ALP), Î³ -glutamyl 
transferase (GGT), and total, direct, and indirect bilirubin are being closely monitored in all clinical studie s to ensure early identification of any potential cases of drug-induced liver toxicity. 
Rigorous stoppi[INVESTIGATOR_736096] (see Section  7). 
2.3.3. Coronavirus Disease 2019 
The coronavirus disease 2019 (COVID- 19) pandemic is active in many countries at the time of 
this protocol amendment. Given this unique circumstance, specific consideration has been given 
to the risks and benefits of the study as they relate to COVID-19, and the global and local 
changes that exist as a result of the pandemic. This assessment is described in Section 10.6. Risk assessment for COVID -[ADDRESS_1005604] been identified: 
â€¢ In patients who have a suboptimal response to eculizumab or ravulizumab, C5 inhibitors have been used to control intravascular hemolysis, leading to reduction of thrombo-embolic events and improved survival. However, 20%-50% of patients 
remain transfusion-dependent due to persistent extravascular hemolysis (EVH), and 
20%-40% of patients exhibit different degrees of residual anemia ( Risitano, 2020). 
Danicopan has a potential mechanistic advantage since it acts upstream of C3 cleavage and has been shown to block C3 fragment deposition. 
â€¢ Patients who only respond partially to eculizumab or ravulizumab due to a genetic polymorphism in CR1 (eg, HindIII H/L and L/L genotypes ( Rondelli, 2014), which 
has been postulated to result in an increased proportion of C3-opsonized RBCs, may have an improved treatment response with danicopan.  
â€¢ Rare patients (~1%) with no response to eculizumab or ravulizumab due to mutations 
in C5 (e.g., Arg885His) ( Nishimura, 2014) could also benefit from danicopan because 
it acts at a different target in the complement cascade and should be unaffected by a 
mutation in  C5. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 29 of 85 
Alexion Confidential  
 3. OBJECTIVES AND ENDPOINTS  
Objectives  Endpoints  
Primary  
â€¢ To evaluate the efficacy of danicopan as 
compared to placebo as add-on therapy to 
a C5 inhibitor at 12 weeks  â€¢ Change  in hemoglobin (Hgb) relative to 
baseline after 12 weeks of treatment with danicopan compared to placebo 
Secondary  
Key Secondary   
â€¢ To evaluate the efficacy of danicopan  on 
Hgb improvement in absence of transfusion as compared to placebo as add-on therapy to a C5 inhibitor at 12 
weeks  â€¢ Proportion of patients with Hgb increase 
of â‰¥ 2 g/dL at Week 12 in the absence of 
transfusion 
â€¢ To evaluate the efficacy of danicopan as 
compared to placebo as add-on therapy to 
a C5 inhibitor on transfusion avoidance at 12 weeks  â€¢ Proportion of patients with transfusion 
avoidance (TA), defined as patients who remain transfusion-free and do not require a transfusion as per protocol- specified 
guidelines through Week 12 
â€¢ To evaluate the effect of danicopan as 
compared to placebo as add-on therapy to a C5 inhibitor on Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue scores for 12 weeks of treatment  â€¢ Change from baseline in FACIT Fati gue 
scores at Week 12  
â€¢ To evaluate the effect of danicopan as 
compared to placebo as add-on therapy to a C5 inhibitor on absolute reticulocyte count â€¢ Change from baseline in absolute 
reticulocyte count at Week 12  
Other Secondary  
â€¢ To evaluate the efficacy  of danicopan as 
add-on therapy to a C5 inhibitor on 
transfusion requirements at 24 weeks for those patients receiving 24 weeks of danicopan  â€¢ Change in the number of red blood cell 
(RBC) units transfused and transfusion instances during the 24 weeks of tre atment 
with danicopan compared to the 24 weeks prior to initiation of treatment with danicopan 
â€¢ Percentage of patients who have transfusion avoidance through 24 weeks of treatment  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 30 of 85 
Alexion Confidential  
 Objectives  Endpoints  
â€¢ To evaluate the efficacy of danicopan  as 
compared to placebo as add-on therapy to 
a C5 inhibitor on transfusion requirements at 12 weeks  â€¢ Change in the number of RBC units 
transfused and transfusion instances during the 12 weeks of treatment with danicopan compared to the 12 weeks while recei ving placebo  
â€¢ To evaluate the effect of danicopan as 
add-on therapy to a C5 inhibitor on 
Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue scores for 24 weeks of treatment  â€¢ Change from baseline in FACIT Fatigue 
scores at Week 24 in all patients 
â€¢ To assess the efficacy of danicopan as 
add-on therapy to a C5 inhibitor on Hgb 
stabilization  â€¢ Percentage of patients with Hgb 
stabilization during the last 12  weeks of 
treatment in patients receiving 24  weeks of 
danicopan 
â€¢ To evaluate the efficacy of danicopan on 
Hgb improvement in absence of transfusion as add-on therapy to a C5 inhibitor at 24 weeks â€¢ Proportion of patients with Hgb increase 
of â‰¥ 2 g/dL at Week 24 in the absence of transfusion 
â€¢ To assess additional laboratory markers 
relevant in PNH pa tients  â€¢ Change from baseline of danicopan treated 
patients compared to placebo in total and direct bilirubin at 12 weeks 
â€¢ Changes in PNH RBC clone size and C3 fragment deposition on PNH RBCs at 12 weeks of treatment with  danicopan 
compared to placebo 
â€¢ Changes in lactate dehydrogenase (LDH) at 12  weeks  
â€¢ Percentage of patients with Hgb normalization at 12 weeks and 24 weeks  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 31 of 85 
Alexion Confidential  
 Objectives  Endpoints  
Exploratory  
â€¢ To assess Patient -Reported Outcomes 
(PRO) and other health-related quality of 
life (QoL) measures during 24 weeks of treatment  â€¢ Change from baseline relative to placebo 
in Three-level EuroQoL 5 dimensions (EQ-5D- 3L) scores at Week  12 
â€¢ Change from baseline in EQ-5D- 3L scores 
at Week 24  
â€¢ Change from baseline relative to placebo in European Organization for Research and Treatm ent of Cancer (EORTC) 
Quality of Life Questionnaire -Core 30 
Scale (QLQ -C30) at Week  12 
â€¢ Change from baseline in EORTC- QLQ-
C30 scale at Week  24 
â€¢ Change from baseline relative to placebo in Work Productivity and Activity Impairment Questionnaire: Anemic Symptoms (WPAI: ANS) at Week  12 
â€¢ Change from baseline in WPAI:ANS scores at Week  24 
â€¢ Change from baseline relative to placebo 
in Healthcare Resource Utilization (HRU) 
at Week  12 
â€¢ Change from baseline in HRU scores at Week  24 
â€¢ To characterize PK and PD of danicopan  â€¢ Plasma concentrations of danicopan over 
time 
â€¢ Changes from baseline in PD biomarkers  
Safety  
â€¢ To evaluate the safety and tolerability of 
24 weeks of treatment with danicopan as add-on therapy to a C5 inhibitor  â€¢ Incidence of treatment -emergent adverse 
events (TEAEs), serious adverse events (SAEs), laboratory abnormalities, and events leading to discontinuation of study drug during Treatment Periods 1 and 2 
â€¢ To evaluate the safety and tolerability of 
danicopan as add-on therapy to a C5 inhibitor during the LTE Period â€¢ Incidence of treatment -emergent adverse 
events (TEAEs), serious adverse events (SAEs), laboratory abnormalities, and events leading to discontinuation of study drug 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005605] clinically evident EVH on a C5 inhibitor (eculizumab or 
ravulizumab). This study will include approximately 84 patients who are receiving a background 
therapy with an C5 inhibitor according to the usual dose and schedule and continue to experience anemia with or without the need of transfusion. Randomization will be stratified by [CONTACT_736137] (ie, > 2 or â‰¤  2 transfusions within 6 months of Screening) and Hgb (ie, < 8.5 g/dL and 
â‰¥ 8.5 g/dL) at Screening, and Japanese patients (defined as patients enrolled from 
Japan)/non- Japanese patients.  
Patients will be randomized to danicopan tid or placebo tid, in a 2:1 ratio for 12 weeks 
(Treatment Period 1) in addition to their background C5 inhibitor (eculizumab or ravulizumab). At Week 12, patients randomized to receiv e placebo will be switched to danicopan for an 
additional 12 weeks (Treatment Period 2) and patients randomized to danicopan will continue on danicopan for an additional 12 weeks while remaining on the ongoing C5 inhibitor therapy. 
This is followed by a 2- year long -term extension (LTE Period), period in which patients will 
continue to receive danicopan + C5 inhibitor therapy.  
In this study, patients will have been on an approved C5 inhibitor for a time period sufficient to 
receive the full benefit of the t herapy but remain anemic. Prolonged therapy with a C5 inhibitor 
alone is not projected to have additional impact on their clinical response. Historical transfusion needs and pretransfusion Hgb levels will be captured for [ADDRESS_1005606] of the  transfusion on the screening Hgb level, which 
will be used for stratification purposes. If patientâ€™s transfusion needs do not allow for this 4- week 
interval, the patient may still be screened.  
Patients will be evaluated for history of vaccination. All patients must be vaccinated against 
meningococcal infections within [ADDRESS_1005607] receive treatment with ap propriate prophylactic antibiotics until 2 weeks after vaccination. 
(see Section 6.5.2).  
The starting dose of danicopan or placebo is [ADDRESS_1005608] at protocol-
specified time points (Week 6, Week 12, and Week 18) (See Section 6.6 dose escalation guidelines). All dose escalations will be made on a patient-by- patient basis at the discretion of 
the Principal Investiga[CONTACT_1639]r [CONTACT_1639] a maximum of [ADDRESS_1005609] 24 weeks of the study but may do so during the LTE Period (see Section  6.5.1).  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 33 of 85 
Alexion Confidential  
 The C5 inhibitor + placebo Group will be dose escalated in the same manner as the 
C5 inhibitor + danicopan Group during the study to maintain the blind to the patient. After all 
patients hav e completed Week 12, the C5 inhibitor + placebo group will switch from placebo to 
danicopan, starting at the [ADDRESS_1005610] some designated visits performed 
either in -clinic or via the home healthcare service provided by [CONTACT_1034]. With this service, the 
patient does not physically visit the investigative site. Instead, a healthcare provider visits the patient at the patientâ€™s r esidence to perform protocol- specified assessments.  
Upon completion of the Treatment Period 2 (Week 24), patients may enter the LTE Period at the same danicopan  dose they were receiving at Week 24, in addition to their background C5 
inhibitor therapy. During the LTE Period, patients may be dose escalated to a maximum of [ADDRESS_1005611] year of LTE (Year 1) and a second year of optional LTE 
(Year 2). All patients will complete 72 weeks of LTE (Year 1) assessments as shown in Table 3. 
After Week 72 (at the end of the first year of LTE), patients have the choice to complete participation in this study or continue to the optional second year of LTE. Once Study 
ALXN2040 -PNH-[ADDRESS_1005612] transition without treatment interruption to Alexion Study ALXN2040- PNH-303, 
completing the End of Treatment Period Visit as soon as possible (no taper or follow up visits are required), or  complete participation in the current study by [CONTACT_736119], plus Taper and Follow Up Visits as soon as possible. See Section 4.4 for definition 
of study completion. 
If a patient discontinues from the study, dosing of study drug should be tapered over 6 days 
(Taper Visit 1 and 2), and a Follow-up Visit will be conducted approximately [ADDRESS_1005613] dose of study drug during the Tapering Period. Patients will continue to receive C5 inhibitor 
therapy at the same dose and interval that they were receiving during the taper and follow-up 
visits.  
4.2. Scientific Rationale for Study Design  
The purpose of this study is to evaluate whether patients with clinically evident EVH on a 
C5 inhibitor therapy (when administered a therapeutic dose), may benefit from the addition of 
danicopan. 
A recent report showed that eculizumab failed to completely block terminal pathway activity in 
several clinically relevant situations ex vivo ( Harder, 2017). Terminal pathway inhibition by 
[CONTACT_736138]. The degree of residual 
terminal pathway activity in the presence of eculizumab correlated with the number of 
surface -deposited C3b molecules. Addition of danicopan to reduce the density of C3b is 
expected to convert the incomplete terminal pathway inhibition by [CONTACT_736139], leading to a synergistic effect. To test this, an in vitro  study was conducted to assess 
the synergy of danicopan combined with eculizumab. The study was performed in an AP-
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 34 of 85 
Alexion Confidential  
 dependent hemolytic assay using RBCs from a PNH patient and 20% normal human serum in the 
presen ce of 10 mM Mg2++EGTA. A strong synergy in protection of PNH RBCs from hemolysis 
was observed, suggesting the potential for a similar synergistic effect in the clinical setting. This 
experiment indicates that danicopan doses of â‰¤  [ADDRESS_1005614] been treated with eculizumab has been completed. The study allowed for dose escalation at 
4-week in tervals through Week 12, with additional escalations permitted after Week 12, based 
on biochemical and clinical response. Results from this ongoing Phase 2 combination study 
continue to demonstrate clinically significant improvements in both the primary and secondary 
endpoints. In addition to the rise in Hgb that has been observed in patients receiving danicopan 
and improvements in reticulocyte counts and bilirubin levels, near elimination of RBC transfusion needs over the 24-week treatment/study period has also been demonstrated. 
Both eculizumab and ravulizumab patients will be included as the C5 inhibitor therapy. Both 
agents are utilized in the real -world setting as a standard of care, those patients who have 
clinically evident EVH on either eculizumab or  ravulizumab will be enrolled in this study. The 
study will enroll at least 35% of the patients with ravulizumab as the C5 inhibitor therapy. 
4.3. Justification for Dose  
Details regarding healthy volunteer dose-ranging studies can be found in the Investigatorâ€™s Brochure. To date, doses up to [ADDRESS_1005615] 
demonstrated clinically significant improvements in Hgb, LDH, and patient reported well-being. 
Treatment has been generally well tolerated.  
The dose range used in the proof of concept study (ACH471-101) was [ADDRESS_1005616] titration based on clinical response to 200 mg tid. Approximately 25% of 
patients in this study were escalated to the 200 mg dose during the 24- week treatment period. 
Patients with abnormalities of ALT and/or direct bilirubin at baseline r eceived a starting dose of 
[ADDRESS_1005617] been identified at starting doses of either 100 or 
150 mg in the danicopan clinical studies. Bas ed on the safety data of all patients treated with 
danicopan in studies ACH471-101, ACH471-103, ACH471-204, and ACH471-205, along with 
the efficacy data observed in study ACH471-101 (danicopan + C5 inhibitor) and PK/PD 
modeling and simulation, the 150 mg dose is considered to be the adequate starting dose for PNH patients.  Therefore, in study ALXN2040- PNH-301, the starting dose of danicopan will be 
150 mg tid. Dose increase will be made based on safety monitoring and Hgb levels and will not exceed 200 mg tid. Patients will continue to receive C5 inhibitor according to their usual dose and schedule. 
The etiology of clinically significant, persistent anemia in the setting of C5 inhibition is 
extravascular hemolysis, which is mechanism based. C5 inhibition with eculizumab, or ravulizumab still allows for C3 cleavage and these cleavage fragments are then deposited on 
PNH RBCs, marking them for extravascular destruction. This process occurs independent of the 
half-life of the C5 inhibitor. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005618] completed 
this study if they:  
â€¢ transition to ALXN2040PNH-303, after completing the end of treatment period visit at any time during the second year of LTE; no taper or follow up visits are needed f or the 
transition  
OR 
â€¢ decide not to transition to ALXN2040- PNH-303, and complete the end of treatment 
period visit at any time during the second year of LTE, plus the taper and follow up visits  
OR 
â€¢ complete Week [ADDRESS_1005619] of the study will be made by [CONTACT_540077]. All appropriate regulatory authorities and IRBs/IECs will be notified of any significant action.  
Each member of the DMC will be required to sign a contract agreement, which includes a 
confidentiality and financial disclosure statement, assuring no conflicts of interest as a condition for membership on the committee.  
The specific responsibilities of the DMC are described in the DMC Charter, which is maintained as a separate document.  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 36 of 85 
Alexion Confidential  
 5. STUDY POPULATION  
5.1. Inclusion Criteria  
Patients are eligible to be included in the study only if all of the following criteria  apply: 
1. Diagnosis of PNH.  
2. Clinically evident extravascular hemolysis (EVH) defined by: 
â€¢ Anemia (Hgb â‰¤  9.5 g/dL) with absolute reticulocyte count â‰¥  120 Ã— 109/L. 
3. Receiving an approved C5 inhibitor for at least 6 months prior to Day 1 in this study at an 
approved dose (or higher) and with no change in the prescribed dose or interval for at 
least [ADDRESS_1005620] the loading dose and 3 
maintenance doses (minimum of 24 weeks) of ravulizumab preceding Day 1. Infusions 
outside the prescribed interval due to a logistical reasons/patient convenience are not 
considered a change in the prescribed interval and should be discussed with the Medical 
Monitor prior to randomization. 
4. Platelet count â‰¥  30,000/ÂµL without the need for platelet transfusions. 
5. Absolute neutrophil counts (ANC) â‰¥  500/Î¼L. 
6. Documentation of vaccination for N. meningitidis : All patients must be vaccinated 
against meningococcal infections within [ADDRESS_1005621] receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination.  
7. Age 18 years or older (or greater than or equal to minimum adult age in accordance with local legal requirements).  
8. Female patients o f childbearing potential must agree to use a highly effective or 
acceptable method of contraception from the date of signing the informed consent until the specified duration after the last dose of their background C5 inhibitor as per the 
product labelling. Female patients of childbearing potential must also have a negative 
serum pregnancy test during Screening and negative urine pregnancy test on Day 1. 
9. Female patients with documented evidence of non-childbearing potential need not employ a method of contr aception.  
10. Nonsterile male patients must agree to use a highly effective or acceptable method of contraception with their partner(s) of childbearing potential from the first day of dosing to [ADDRESS_1005622] dose of study drug. 
â€¢ Males who are surgically sterile need not employ additional contraception.  
â€¢ Males must agree not to donate sperm while enrolled in this study and for [ADDRESS_1005623] dose of study drug. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 37 of 85 
Alexion Confidential  
 11. Capable of giving signed informed consent as described in Appendix 1 which includes 
compliance with the requirements and restrictions listed in the informed consent form 
(ICF) and in this protocol. 
12. Must have access to emergency medical care.  
13. Patients who are on iron, folic acid, and vitamin B [ADDRESS_1005624] 30 days prior to Day 1. See Section 6.5.   
5.2. Exclusion Criteria  
Patients are excluded from the study if any of the following criteria apply: 
1. History of a major organ transplant (e.g., heart, lung, kidney, liver) or HSCT.  
2. Known aplastic anemia or other bone marrow failure that requires HSCT or other therapi[INVESTIGATOR_247849]-thymocyte globulin and/or immunosuppressants, unless the 
dosage regimen of immunosuppressant has been stable for at least 12 weeks before Day 1 
and patient is expected to remain on stable doses through Week 24 (see Section 6.5).  
3. Received another investigational agent other than C5 inhibitors (eculizumab or 
ravulizumab) within 30 days or 5 half-lives of the investigational agent prior to study 
entry, whichever is gre ater.  
4. Known or suspected complement deficiency. 
5. Known underlying bleeding disorders (eg, coagulation factor deficiencies, idiopathic thrombocytopenic purpura, Von Willebrand disease, etc.) or any conditions leading to anemia that are not primarily due to PNH.  
6. Active bacterial or viral infection, a body temperature >38Â°C on two consecutive daily measures, evidence of other infection, or history of any febrile illness within [ADDRESS_1005625] study drug administration. 
7. History or presence of any clinically relevant co -morbidities that would make the patient 
inappropriate for the study (eg, is likely to result in deterioration of the patientâ€™s condition, affect the patientâ€™s safety during the study, or confound the results of the study). 
8. Laboratory abnorm alities at screening, including: 
â€¢ ALT >  2 Ã— ULN (> 3 Ã— ULN in the case of patients with documented liver iron 
overload defined by [CONTACT_736120] â‰¥  500 ng/mL). The inclusion of patients 
with documented iron overload and ALT > 2 Ã— ULN will be done in a case by [CONTACT_413], with prior discussion with the Medical Monitor. 
â€¢ Direct bilirubin >  2 Ã— ULN, with the exception of: 
o patients who, in the opi[INVESTIGATOR_8925], have direct bilirubin > 2 Ã— ULN due to EVH and/or  
o patients with documented Gilbertâ€™s syndrome (if Gilbert's syndrome is suspected, the patient will be tested for this condition at screening). See Section  8.1 for details.  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 38 of 85 
Alexion Confidential  
 9. Any other clinically significant laboratory abnormality as judged by [CONTACT_49229], 
in the opi[INVESTIGATOR_1237], would make the patient inappropriate for the 
study or put the patient at undue risk. 
10. Females who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration. 
11. Current evidence of biliary cholestasis. 
12. Evidence of hepatitis B (positive hepatitis surface antigen [HBsAg] or positive core 
antibody [anti-HBc] with negative surface antibody [anti- HBs]) or hepatitis C viral 
infection (HCV antibody positive), except for patients with documented successful 
treatment and documented sustained virologic response (SVR) at Screening 
13. Evidence of human immunodeficiency virus (HIV antibody positive) infection at Screening  
14. Estimated glomerular filtration rate (eGFR) <30  mL/min/1.73 m
2 and/or are on dialysis. 
15. Hypersensitivity to the investigational drug (danicopan) or any of its excipi[INVESTIGATOR_840] 
5.3. Screen Failures  
Screen failures are defined as patients who consent to participate in the clinical study but are not subsequently entered in the study. The Investigator must maintain a log of screen failure patients 
that includes, at a minimum, demography, screen failure details, eligibility criteria, and any 
serious adverse events (SAEs) occurring after providing informed consent. 
Prospective patients should be screened within [ADDRESS_1005626] be completed before the patient is accepted into the study. If the patient is 
unable to receive study drug within 45 days of screening, the patient may be rescreened once. 
Repeating any screening lab oratory result(s) may be permitted on a case- by-case basis with the 
approval of the Medical Monitor (or designee). In these instances, repeating of a single 
laboratory test or a subset of the full panel may be acceptable. 
For patients screened more than [ADDRESS_1005627] sign a 
new ICF but should be assigned the same patient number as for the initial screening. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 39 of 85 
Alexion Confidential  
 6. STUDY DRUG  
â€œStudy Drugâ€ in this protocol refers to danicopan or matching placebo. 
Patients should take all doses of study drug approximately 15 to 30 minutes after eating a meal 
or snack. Water intake is not restricted.  
6.1. Study Intervention Administered  
 
Table 5: Study Interventions Administered  
Compound Name  [CONTACT_736166] (ALXN2040)  Placebo  
Type  Drug  Placebo  
Dose Formulation  Tablet  Tablet  
Unit Dose Strengths  50 mg; 100 mg  50 mg; 100 mg  
Dosage Levels  150 mg; 200 mg  150 mg; [ADDRESS_1005628] until their next study visit. On visits when PK/PD sampling is scheduled, the patients 
will be instructed to take their dose at the clinic to enable predose sampling. At dose escalation decision visits, patients will return to the clinic to be dispensed study drug and receive new dosing instructions. See time points in Section 1.2. 
6.2. Preparation/Handling/Storage  
At the pharmacy, study drug must be stored as provided at controlled room temperature (20Â°C to 25Â°C), with allowed excursion of 15Â°C to 30Â°C. Patients should be instructed to keep their study drugs in the original container at room temperature. 
The Principal Investigator [INVESTIGATOR_1461] (e.g., pharmacist) is responsible for ensuring storage as 
per the label on the drug product at the site and adequate accountability of all used and unused study drug. This includes acknowledgment of receipt of each shipment of study drug (quantity 
and condition) and patient dispensing records and returned or destroyed drug. Dispensing records 
will document quantities received from the Sponsor. (or designee) and quantities dispensed to patients, including lot number, date dispensed, and patient identifier number. All drug supplies 
and associated documentation will be periodically reviewed and verified by [CONTACT_736140]. 
6.3. Measures to Minimize Bias: Randomization and Blinding  
This is a double-blind, placebo-controlled Study with 2:1 randomization. The randomization 
scheme will be stratified by [CONTACT_736118] (ie, > 2 or â‰¤  2 transfusions within 6 months of 
Screening), Hgb (ie, < 8.5 g/ dL and â‰¥ 8.5 g/dL) at Screening, and Japanese patients (defined as 
patients enrolled from Japan)/non- Japanese patients. The stochastic dynamic allocation rules on 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 40 of 85 
Alexion Confidential  
 the stratification factor will be used to assign patients to either danicopan or placebo trea tment 
group at a 2:1 ratio through an interactive response technology (IRT) system on Study Day 1.  
Although all patients will receive active drug during Treatment Period 2 and LTE Period, the 
treatment arm assignment during Treatment Period 1 will not be unblinded until after database lock occurs. 
The IRT will be programmed with blind-breaking instructions. In the event that emergency 
unblinding is necessary, the IRT will provide clear step-by-step instructions for the investigator to follow. Details are a lso provided in the IRT Site User Guide.  
In case of an emergency, the investigator has the sole responsibility for determining if unblinding of a participantsâ€™ intervention assignment is warranted. Participant safety must always be the first 
consideration in making such a determination. If the investigator decides that unblinding is 
warranted, the investigator should make efforts to contact [CONTACT_736141] a participantâ€™s intervention assignment unless this could delay emergency treatment of the 
participant. If a participantâ€™s intervention assignment is unblinded, Alexion must be notified 
within [ADDRESS_1005629] be recorded in the patientâ€™s electronic case report form (eCRF). The 
following are some general guidelines for concomitant medication use based on currently 
available data:  
â€¢ Concomitant administration of folic acid, and/or erythropoiesis- stimulating agents is 
permitted if on stable doses for at least 30 days prior to Day 1; patients should be 
maintained on stable doses (without any modifications of quantity or frequency) of 
these agents t hrough Week 24. 
â€¢ Concomitant administration of steroids or other immunosuppressants is permitted if the dosage regimen is stable for at least 12 weeks before Day 1 and remain on stable doses through Week 24. 
â€¢ Oral, injectable, implantable, transdermal, or in travaginal hormonal therapi[INVESTIGATOR_736097]. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 41 of 85 
Alexion Confidential  
 â€¢ Prophylactic antibiotics may be administered if deemed appropriate by [CONTACT_736142]/or guidelines for treatment with a complement inhibitor. B ecause 
commercially available products will be used, information about any specific 
antibiotics administered can be found on the package inserts/product labels for those 
products. 
The use of concomitant medications during the study will be assessed at the time points indicated in Table 1. 
6.5.1. Background C5 Inhibitor Therapy: Eculizumab and Ravulizumab  
All patients are to be treated with study drug in combination with a C5 inhibitor therapy (i.e., 
eculizumab or ravulizumab ) at the approved dosages for the purpose of data collection and 
analysis. C5 inhibitor used in this manner will be considered a background therapy. If patients 
switch to a different approved C5 inhibitor after completion of the study at Week 24, the new medication used in this manner will be also considered a background therapy. 
Approved C5 inhibitor dose may not be increased, nor interval shortened, during this study (with 
the exception of ravulizumab weight-based dosing based on changes in weight). The dose of the 
C5 inhibitor may be decreased, if indicated, with a dose re-escalation to the prior dose if the dose 
reduction was not tolerated. 
Changes in frequency of C5 inhibitor administration that are due to patient convenience or 
logistical reasons, but do not result in a change of the prescribed dosage and frequency are 
considered stable and should be discussed with the Medical Monitor prior to randomization. 
Patients may not switch from their Day [ADDRESS_1005630] 
24 weeks of the study but may do so during the LTE period. The only authorized switch is from 
eculizumab to ravulizumab (possible only in those countries where ravulizumab is commercially available).  
C5 inhibitor therapy will be provided according to local regulations and approvals. 
6.5.2. Vaccines  
To reduce the risk of meningococcal infection, all patients must be vaccinated against 
meningococcal infections within [ADDRESS_1005631] be vaccinated or revaccinated according to current national vaccination guidelines 
or local practice for vaccination use with complement inhibitors (eg, Advisory Committee on 
Immunization Practices ([ACIP])). Vaccination may not be sufficient to prevent meningococcal infection. All patients should be monitored for early signs of meningococcal infection, evaluated immediately if infection is suspected, and treated with appropriate antibiotics, if necessary. 
Any patient without sufficient history of these vaccines may be vaccinated or provided boosters, 
as appropriate. Vaccinations and/or boosters may be administered either during the screening period, after all other screening assessments have been completed, or on once study drug 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005632] on the days of vaccination before any vaccine or booster is administered. 
For any vaccines or boosters given as part of this study, full identifying information, including 
the brand, should be recorded in the patientâ€™s eCRF. 
6.6. Study Drug Dose Modification  
Doses of study drug (danicopan or placebo) may be escalated to a maximum of [ADDRESS_1005633], at specified time points during the initial treatment period and during the LTE Period using the criteria below. All dose escalations decisions wi ll be made 
based on central laboratory data and at the discretion of the Principal Investigator, in consultation with the sponsor. This applies to both Treatment Periods 1 and 2. The C5 Inhibitor + Placebo Treatment Group will be escalated in the same mann er as the C5 Inhibitor + Danicopan 
Treatment Group during the study to maintain the blind. 
6.6.1. Dose Escalation During Treatment Period [ADDRESS_1005634] dose at the following time points: 
â€¢ At the Week 6 Visit, if the patientâ€™s Hgb level at Week 4 has not increased by â‰¥2 g/dL from their baseline value (Day 1), or the patient received a transfusion during 
the previous 4 weeks.  
â€¢ At the Week 12 Visit , if the patientâ€™s Hgb level at Week [ADDRESS_1005635] the midpoint of the normal range for gender from their baseline value or the patient received a transfusion during the previous 4 weeks. 
6.6.2. Dose Escalation During Treatment Period 2  
â€¢ At th e Week 18 Visit, if the patientâ€™s Hgb level at Week [ADDRESS_1005636] the midpoint of the normal range for gender from their baseline value (Day 1) or the patient received a transfusion during the previous 4 weeks. 
6.6.3. Dose Escalation During th e LTE Period  
â€¢ Any patient who has not already been dose escalated up to [ADDRESS_1005637] 4 weeks and the Investigator believes that additional 
efficacy can be achieved. Dose escalations after Week 24 visit will be discussed with 
the sponsor before being implemented.  
6.6.4. Monitoring After Drug Escalation  
â€¢ If a patient has been dose escalated, laboratory blood samples for measurement of 
standard laboratory safety assessments should be obtained at the next week visit 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 43 of 85 
Alexion Confidential  
 following the escalation, either in clinic or via the visiting healthcare service as per 
the schedule of assessments.  
At any time -point after the dose escalation, if patient safety or tolerability warrants dose 
reduction to the previous dose this may occur in consultation with the Sponsor. This dose 
reduction will only occur, if both Principal Investigator [INVESTIGATOR_736098].  
Any patient who is at a dose of 100 mg tid upon implementation of this amendment, should be 
escalated to 150 mg tid at the next clinic visit (an unscheduled visit may be used for this purpose) 
and subsequently should follow the dose escalation guidelines outlined above.  
6.7. Dose Interruptions  
If danicopan dose is interrupted for any reason, an assessment should be made if the stop is 
temporary or the patient is to be withdrawn based on the criteria described in Section 7. Discussion 
about the reasons for interruption and plans for potential re -initiation should occur between the 
Investigator and the Alexion Medical Monitor. Re -initiation of treatment with danicop an should 
be done under careful clinical monitoring, including laboratory monitoring and after consultation with the Alexion Medical Monitor. If upon resumption of treatment, the patient has a recurrence of the event, permanent discontinuation should be considered as described in Section 7.1. 
Any temporary preplanned treatment interruption should be discussed between the Investigator 
and the Alexion Medical Monitor and tapering should be considered (refer to Section 7.2).  
The patient should continue participation until the end of the study unless the prespecified events 
for treatment discontinuation have been met. Any interruption of study drug and the reason for the interruption should be fully documented in the source documents and eCRF. 
6.8. Transfusion Guidelines Before and During the Study  
It is recommended to administer pRBC transfusion when a subject has a 
1. Hemoglobin value of less than 7 g/dL regardless of presence of clinical signs or symptoms, or 
2. Hemoglobin value of less than 9 g/dL with signs or symptoms of sufficient severity to warran t a transfusion. 
In the event of life-threatening anemia, transfusion of ABO- and RhD-matched blood is appropriate. If further matching for Kell and JK antigens can be conducted without delaying making the blood available for emergent transfusion, this additional testing is recommended. The 
reason for transfusion as well as signs or symptoms associated with the subjectâ€™s need for 
transfusion, will be documented on the electronic case report form (eCRF) for each individual subject. Typi[INVESTIGATOR_65079]- related sym ptoms warranting transfusions include angina, change in 
mental status, syncope, light headedness, confusion, shortness of breath, and fatigue. 
The Investigator will determine the appropriate number of units of pRBCs to be transfused. In 
the event of a tran sfusion is required, a blood sample for central lab is to be collected as an 
assessment prior to transfusion. Administration of transfusion including the reason for 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 44 of 85 
Alexion Confidential  
 transfusion (hemoglobin result, signs, and symptoms) and the number of units transfused, wi ll be 
documented in the eCRF. 
6.9. Intervention After the End of the Study  
If study drug (danicopan or placebo) is discontinued for any reason, the dose will be tapered over 
a 6-day period as described in Section 7.[ADDRESS_1005638] dose of study drug.  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005639] dose of study drug to be evaluated 
for AEs.  
A patient is free to withdraw from the study at any time without jeopardizing future medical care. In addition, the Principal Investigator (or designee) may decide, for reasons of medical 
prudence or patient noncompliance, to discontinue dosing of study drug for an individual patient. The Principal Investigator [INVESTIGATOR_736099], and should notify the Medical Monitor immediately, and if possible, before 
dosing is terminated. Patients will continue to receive C5 inhibitor therapy, as per the Principal Investigatorâ€™s judgment but the study drug will be permanently discontinued. 
Reasons for patient withdrawal may include:  
â€¢ Intercurrent illness that would, in the judgment of the Investigator, affect assessment 
of clinical status to a significant degree  
â€¢ Development of any of the following liver function test abnormalities in the absence of hemolysis:  
âˆ’ ALT > 8 Ã— ULN  
âˆ’ ALT > 5 Ã— ULN for more than 2 weeks 
- Increase of ALT > 3 Ã— ULN and > 3 Ã— from baseline and total bilirubin 
> 2 Ã— ULN or INR > 1.5, in the absence of warfarin anticoagulation 
- Increase of ALT > 3 Ã— ULN and > 3 Ã— from baseline with the appearance of 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%)  
â€¢ Patient withdrawal from their background C5 inhibitor. Investigators should follow 
the instructions on discontinuation and monitoring of the patient as outlined in the 
approved corresponding Summary of Product Characteristics (SmPC)/Local Product Information for eculizumab or ravulizumab. 
â€¢ Persistent Grade 3 -4 toxicity (including a c linically significant laboratory 
abnormality) despi[INVESTIGATOR_736100], in the judgment of the Investigator, compromises the ability to 
continue study-specific procedures, or it is considered not to be in the patientâ€™s best interest to continue the study  
â€¢ Patient request to discontinue for any reason 
â€¢ Pregnancy or planned pregnancy 
â€¢ Patient non- compliance  
â€¢ Discontinuation of the study at the request of the Sponsor, regulatory agency, or Ethics Committee or IRB  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 46 of 85 
Alexion Confidential  
 â€¢ Any other condition or circumstance that would jeopardize the welfare of the patient 
if s/he were to continue in the study 
â€¢ The reason for any patientâ€™s discontinuation and the date of withdrawal will be recorded in the patientâ€™s eCR F. The patientâ€™s eCRF, which will be completed up to 
the point of withdrawal, will be retained for the sponsor. If a patient discontinues from the study for any reason, all protocol procedures as defined in Table [ADDRESS_1005640] observation of ALT 3 Ã— baseline, a repeat test must be performed (ALT, AST, direct bilirubin, and INR) within [ADDRESS_1005641] the patient and inquire about the presence of any symptoms (fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, or rash). 
If necessary for safety reasons, local laboratories are permitted to id entify patients that may need 
to be discontinued from the study and results need to be discussed with the Medical Monitor, 
however the final discontinuation from the study requires central laboratory determinations and 
discussion with the Medical Monitor  
If the patient withdraws consent for disclosure of future information, the sponsor may retain and 
continue to use any data collected before such a withdrawal of consent. If a patient withdraws 
from the study, he/she may request destruction of any samples taken and not tested, and the Investigator must document this in the site study records. 
7.1. Study Stoppi[INVESTIGATOR_2121]  
A consideration for the dosing to be terminated may be implemented based on DMC recommendation, if one or more of the following occurs (see Section 2.3.2 on risks of liver 
enzyme elevations):
 
â€¢ Two or more patients discontinue study therapy due to liver function test abnormalities as detailed be low 
âˆ’ ALT > 8 Ã— ULN  
âˆ’ ALT > 5 Ã— ULN for more than 2 weeks 
- Increase of ALT > 3 Ã— ULN and > 3 Ã— from baseline and total bilirubin > 2 Ã— ULN or INR > 1.5, in the absence of warfarin anticoagulation 
- Increase of ALT > 3 Ã— ULN and > 3 Ã— from baseline with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%)  
Because patients may experience hemolysis which may result in increased bilirubin AST and even ALT, increases in bilirubin AST and/or ALT during the study must be evaluated in the 
context of hemolysis. The Principal Investigator [INVESTIGATOR_736101], as well as 
baseline bilirubin AST and ALT levels, to determine if the increases observed are due to an effect on liver function or are secondary to hemolysis. Any liver function test elevation felt to be 
associated with hemolysis (and not caused by [CONTACT_5349]) will not be included in study stoppi[INVESTIGATOR_736102]. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 47 of 85 
Alexion Confidential  
 Anytime a patient has to discontinue the study drug, the dose tapering instructions and schedule 
(see Section 7.2 and  Table 6) should be followed unless the patient cannot tolerate tapering of 
study drug or the discontinuation is due to an SAE. 
7.2. Dose Taper  
If the study drug is discontinued or the dose is interrupted (Section 6.7), the dose of danicopan or placebo will be tapered over a 6 -day period. The dosing taper regimen is described in Table 6. In 
addition, the taper schedule may be adjusted to allow for slower taper in a patient who is not 
tolerating discontinuation of drug. 
If the patient withdraws from the study at any time, the patient will complete the Early 
Terminatio n visit as soon as possible prior to tapering. Patients should take the study drug per 
protocol until the tapering period begins. 
Table 6: Study Drug Taper Schedule  
Danicopan  or Placebo Dose at 
Termination  Taper Period 1 (T1)  
(Taper Days 1 -3) Taper Period 2 (T2)  
(Taper Days 4 -6) 
150 mg tid  100 mg tid  50 mg tid  
200 mg tid  100 mg tid  50 mg tid  
Abbreviations: tid  = three times per day; T = taper  
T1 and T2 visits may be done by [CONTACT_736143] 3 and Day 6, respectively.  
T1 visit can be combined with the Early Termination visit if the patient discontinues prior to Week 12. 
T1 should assess safety and give instructions to taper dosing. T2 should give instructions to terminate dosing.  
Patients will continue to receive their approved C5 inhibitor at the same dose and interval during 
the taper and follow-up period that they were receiving during the treatment period. 
7.2.1. Follow- up Period  
After completion of the taper period, patients will enter the Follow-up Period. Patients will be 
evaluated at the clinical site 30  (+ 7)  days after the last dose of study drug (danicopan or 
placebo). During the Follow-up Period, physical examinations, assessment of vital signs, all 
required safety laboratory testing, and collection of blood and urine samples will be performed at 
various time points in the clinic as specified in Table 3. 
7.3. Lost to Follow up  
A patient  will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contact[CONTACT_9298]. 
The following actions must be taken if a patient fails to return to the clinic for a required study 
visit:  
â€¢ The site must attempt to contact [CONTACT_736144]/or should continue in 
the study. 
â€¢ Before a patient is deemed lost to follow up, the Investigator or designee must make every effort to regain contact [CONTACT_10970] (where possible, 3 telephone calls and, if necessary, a certified letter to the patientâ€™s last known mailing address or local 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 48 of 85 
Alexion Confidential  
 equivalent methods). These contact [CONTACT_23526]â€™s 
medical record.  
â€¢ Should the patient continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study as a whole are handled as part of  Appendix 1. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 49 of 85 
Alexion Confidential  
 8. STUDY ASSESSMENTS AND PROCEDURES  
The required study assessments procedures are described in this section. The timeline for all 
procedures may be found in Section 1.2.  
8.1. Screening Period  
The Principal Investigator [INVESTIGATOR_736103]- related procedures are 
performed. Each patient will sign (written or electronic) an ICF (see Section  10.1.3). This may 
include additional consent forms for human immunodeficiency virus testing or other procedures which may be performed prior to patients being accepted into the study. 
A window of up to [ADDRESS_1005642] be performed and documented prior to dosing. This will include a review of the inclusion and exclusion 
criteria. The patientâ€™s medical history will be reviewed, and a complete physical examination 
will be conducted. The medical history should include the patient's transfusion history of a minimum of [ADDRESS_1005643] be performed as early as possible in 
the screen ing period to identify and initiate iron supplementation, if clinically indicated, in 
patients with iron deficiency. Patients on iron, folic acid and/or B
[ADDRESS_1005644] be negative to be eligible for 
the study. 
All laboratory assessments for eligibility are performed by [CONTACT_2237]. However, use 
of local laboratories to determine eligibility will be permitted if the central laboratory cannot 
initially provide results for the following assessments: platelets, ANC, direct Coombs, D-dimer, and INR. If local laboratories are used to determine eligibility for the assessments stated above, a 
central laboratory sample should be obtained pre-dose on Day 1 to establish the patientâ€™s 
baseline values. Use of local laboratory values for eligibility s will need to be discussed with the Medical Monitor. 
If screening laboratory assessments show elevated indirect  bilirubin levels in conjunction with 
normal liver function tests (AST and ALT), or if the patient has a history of unexplained 
jaundice, unexplained high bilirubin levels, or a history otherwise suggestive of Gilbert's 
syndrome, the patient will be tested for this condition. If the patient has a history of Gilbertâ€™s 
syndrome it should be documented as the patientâ€™s medical history. Refer to the Laboratory Manual for testing procedure.
 
If the patient is unable to receive study drug within 45 days of screening, the patient may be rescreened once. The repeating of individual screening laboratory results that fall outside the reported normal range may be permitted on a case -by-case basis with the written preapproval of 
the Medical Monitor (or designee). 
As part  of the screening process, patients will be evaluated for vaccination requirements as 
detailed in Section  6.5.2. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 50 of 85 
Alexion Confidential  
 8.2. Efficacy Assessments 
Blood will be collected according to the Schedule of Assessments (see Section  1.2) to assess the 
efficacy endpoints of change in hemoglobin, reticulocyte counts, bilirubin, and lactate 
dehydrogenase. PNH RBC clone size, C3 fragment deposition on PNH RBCs, AP and classical pathway activities, and Bb, C3, FD, and free C5 levels will also be assessed. Blood collection procedures are described in Section  [IP_ADDRESS]. 
Transfusion data, including the number of RBC units transfused, the associated pre-transfusion hemoglobin value (with reticulocyte count, if available) and the reason for transfusion will be 
collected from the time of screening until follow -up (from study site records and any other 
location where the patient receives any transfusions) and recorded in each patientâ€™s eCRF.  
Given that the primary endpoint of the study is change from baseline in Hgb after treatment with danicopan vs placebo, and PNH RBCs are more prone to hemolysis during sample collection, 
management, and/or shipment, a backup central hematology sample must be obtained at the Week 12 and Week 24 visits for all patients.  
8.3. Patient -Reported Outcomes  
All patients enrolled in the study will self -administer questionnaires for the FACIT- Fatigue 
(Version 4), European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30 Scale (QLQ -C30), and EQ-5D- 3L (Visual Analogue Scale and Time 
Trade Off scores ) scales and Work Productivity and Activity Impairment Questionnaire: Anemic 
Symptoms V2.0 (WPAI: ANS) (see Section 1.2). Local language versions of each of the tools will be provided separately. 
Health Resource Utilization data will be collected as per schedule shown in Section  1.2. For 
HRU, the Investigator or designee will record for each participant the number of clinic visits, 
emergency services utilized, hospi[INVESTIGATOR_059], missed work and also record the number of times the patient had darkened urine. Local language versions of each of the tools will be provided separately.  
All PROs and QoL assessments (written or electronic) will be administered before the treatment dose on Day 1. On other clinic visits, PROs and QoLs should be administered as early as 
possible. If patient is to receive infusion of their C5 inhibitor agent on a clinic visit where PROs 
and QoLs will be obtained, it is recommended that patients fill out the PRO and QoL instruments before the C5 inhibitor infusion.  
8.4. Safety Assessments and Procedures  
Safety will be evaluated by [CONTACT_736145], clinical laboratory tests, physical examination findings, and vital signs measurements. Planned time points for all safety assessments are provided in  Section  1.2. All findings must be recorded in the patientâ€™s source 
documents and in the patientâ€™s eCRF. 
8.4.1. Clinical Laboratory Tests 
Blood and urine samples will be collected for efficacy, safety, and PD laboratory evaluation as 
listed in Table 7 in Appendix 2 at the times indicated in S ection  1.2. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005645] indicator is considered necessary by [CONTACT_3786], it should be discussed with the Medical Monitor and the procedures described for 
unblinding (see Section 6.3) and discontinuation of the patient from the study (see Section 7) should be followed.
 
[IP_ADDRESS]. Blood Collection 
Patients will be in a seated or supi[INVESTIGATOR_736104]. Specific instructions for sample collection, processing, and shippi[INVESTIGATOR_22016] a separate laboratory manual. If central laboratory tests results are not obtainable in a timely manner, samples may be collected 
at an unscheduled visit and analyzed locally. See the laboratory manual for additional 
information. 
Unanticipated additional blood may be collected throughout the study for safety monitoring and 
additional PD assessments, if necessary.  
8.4.2. Physical Examinations 
A complete physical examination will be per formed at Screening and on Day 1 and will include 
an assessment of general appearance and a review of systems. Height (at screening only) and 
weight will also be measured and recorded. Measurements of height and weight should be taken 
with the patients in light clothing or underwear and without shoes. 
A brief physical examination will be conducted at all other in- clinic visits, as indicated in 
Section  1.2. Additional brief, complete, or symptom-driven physical examinations may be 
conducted at the discretion of the Investigator or designee and/or when patients present with 
AEs.  
8.4.3. Vital Signs  
The Principal Investigator [INVESTIGATOR_736105], heart rate, and respi[INVESTIGATOR_736106]  1.2. Vital signs will be measured following a 5- minute rest. 
Vital sign values will be recorded in the patientâ€™s source documents and in patientâ€™s eCRF. 
8.4.4. Electrocardiograms  
The Principal Investigator [INVESTIGATOR_736107] (ECG) measurements at the 
times indicated in Section  1.2. All ECG recordings will be 12- lead and will be performed after 
the patient has rested quietly for at least 5  minutes in a supi[INVESTIGATOR_736108] 
(whenever possible). The following parameters and intervals will be assessed: HR, RR, PR, QRS, QT, and QTcF. The occurrence of depolarization or repolarization disorders, arrhythmic disorders or other abnormalities will be noted. 
In some cases, it may be appropriate to r epeat an abnormal ECG to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that the leads are placed in 
approximately the same positions each time in order to achieve precise ECG recordings.  
All ECGs must be read by [CONTACT_079] [INVESTIGATOR_1461]. All ECG parameters and assessments must be recorded or stored in the patientâ€™s source documents and in patientâ€™s eCRF. Any clinically significant finding must be reported as an adverse event. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 52 of 85 
Alexion Confidential  
 8.5. Adverse Events and Serious Adverse Events  
The definitions of an AE or SAE are in Appendix 3. Adverse events will be reported by [CONTACT_4677] (or, when appropriate, by a caregiver, surrogate, or the patient's legally authorized 
representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up on all AEs including those that are serious, considered related to the study intervention or study procedures, or that caused the patient to discontinue the study intervention. 
8.5.1. Time Period and Frequency for Collecting AE and SAE Information  
All AEs and SAEs will be collected from the signing of the ICF until [ADDRESS_1005646]-
treatment complications that occur as a result of protocol-mandated procedures (e.g., invasive procedures, such as venipuncture or biopsy), which should be reported as AEs. Pregnancy is not 
considered an AE. A pregnancy occurring after the start of study intervention should be reported 
on the pregnancy forms, as described in Section 10.3.8. 
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 3. The investigator will 
submit any updated SAE data to the sponsor within 24 hours of it being available. 
Investigators are not obligated to actively seek AEs or SAEs after conclusion of the study 
participation . However, if the Investigator learns of any SAE, including a death, at any time after 
a pati ent has been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention or study participation, the Investigator must promptly notify the sponsor, (i.e., within 24 hours of the Investigator becoming aware of the event); such events are 
not entered into the eCRF). 
8.5.2. Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3. 
8.5.3. Follow- up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each patient at 
subsequent visits/contac ts. All SAEs will be followed until resolution, stabilization, the event is 
otherwise explained, or the patient is lost to follow-up (as defined in Section 7.3). Further information on follow-up procedures is given in Appendix 3. 
8.5.4. Regulatory Reporting Requirements for SAEs  
Prompt notification by [CONTACT_11012] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of patients and the safety of a study 
intervention under clinical investigation are met.  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 53 of 85 
Alexion Confidential  
 The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
sponsor will ensure compliance with country-specific regulatory requirements relating to safety reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and investigators. 
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) will be reported according to local 
regulatory requirements and sponsor policy and forwarded to investigators as necessary. 
An Investigator who receives an investigator safety report describing a SAE or other specific 
safety information (e.g., summary or listing of SAEs) from the sponsor will review and then file it along with the Investigatorâ€™s Brochure and will notify the IRB/IEC, if appropriate according to local requirements.  
8.5.5. Pregnancy  
Details of any pregnancy in female patients and/or female partners of male patients that occurs or is confirmed within the timelines listed in Section  8.5.1 will be collected. If a pregnancy is 
reported, the investigator should inform the sponsor within one business day of learning of the pregnancy and should follow the procedures outlined in Appendix 3 and Appendix 4. 
Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.  
8.6. Treatment of Overdose  
For this study, any dose of study drug greater than the prescribed dose within a 24-hour period will be considered an overdose. 
The Sponsor does not recommend specific treatment for an overdose; general supportive 
measures are recommended as below.  
In the event of an overdose, the Investigator/treating physician should: 
1. Based on the Investigatorâ€™s judgement, contact [CONTACT_1034]â€™s Medical Monitor  
2. Assess the patient and determine the need for any monitoring in a medical setting; if the Investigator cannot see the patient or the patient cannot reach the Investigator, the patient should go to the emergency room  
3. Closely monitor the patient for any untoward effects of the overdose 
4. Any overdose reported by [CONTACT_102] (purposeful or accidental) should be recorded as an AE at minimum and ass essed for seriousness as appropriate  
5. If necessary, based on consultation with the Sponsorâ€™s Medical Monitor, obtain a plasma sample for PK analysis or safety labs  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_116333]â€™s Medical Monitor. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 54 of 85 
Alexion Confidential  
 8.7. Pharmacokinetics  
Pharmacokinetics (PK) will be evaluated using plasma from whole blood collected during the 
study as outlined in Section 1.2. Study drug concentration information that may unblind the 
study will not be reported to investigative sites or blinded personnel until the study has been unblinded. Additional information on sample collection and shippi[INVESTIGATOR_70533] a separate laboratory manual.  
8.8. Pharmacodynamics  
Pharmacodynamics will be evaluated using serum (for AP activity, C3, CP activity, and free C5) and plasma (for Bb and FD) from whole blood collected during the study as outlined in Section  1.2. PD assessments that may unblind the study will not be reported to investigative sites 
or blinded personnel until the study has been unblinded. Additional information on sample collection and shippi[INVESTIGATOR_70533] a separate laboratory manual. The Sponsor may store samples for other biomarker tests for future research subject to local and regional regulatory approval.  
8.9. Genetic Samples  
Subject to patient consent, a sample will be collected at baseline (Day 1) for potential genetic analysis Appendix 5: Genetics . Genetic analyses may be conducted: 1) if a patient does not 
respond to the investigative drug; 2) if a patient experiences drug- related toxicity; or 3) to further 
characterize the underlying disease.  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 55 of 85 
Alexion Confidential  
 9. STATISTICAL CONSIDERATIONS  
9.1. Statistical Hypotheses  
The null statistical hypothesis is the improvement in hemoglobin level from baseline at Week 12 
for danicopan being similar to the improvement for placebo; defined as the difference in mean chang e from baseline between danicopan and placebo at Week [ADDRESS_1005647] hemoglobin levels, on the average, of 10.5 g/dL ( McKinley, 2017) . All 
patients entering this study will have a hemoglobin level of â‰¤ 9.5 g/dL. A minim um of 2 g/dL in 
difference between danicopan and placebo treatments in terms of mean improvement from baseline after 12 weeks of treatment is, considered clinically meaningful.  
A total of approximately 84 patients will be enrolled into this study and randomized in a 2:1 ratio to danicopan and placebo study arms. It is anticipated that approximately 10% of patients will discontinue prior to the primary endpoint. For the primary endpoint of change from baseline to 
Week [ADDRESS_1005648] is 99% to detect the 
difference in mean change from baseline of 2 g/dL (alternative hypothesis), assuming the 
statistical significance level of 0.05 (two -sided) and the standard deviation of 1.6 g/dL, which is 
estimated from study ACH471-101. For the key secondary endpoint of patients with Hgb increase of â‰¥ 2 g/dL at Week 12 in the absence of transfusions, the study has >95% power assuming at least 35% of patients in the danicopan arm and 5% of patients in the placebo arm 
can meet the criterion. For the key secondary endpoint of patients with TA, the study has 70% 
power for the TA endpoint assuming 90% of patients in the danicopan arm and 64% of patients 
in the placebo arm will have TA. For the key secondary endpoint of change from baseline to 
Week 12 in FACIT-Fatigue score, the study has 91% power with a two- sample t- test to detect a 
9-point difference between treatment arms in mean change from baseline, which is considered 
clinically meaningful. The power calculation is based on the assumption of a standard deviation 
of 11 for FACIT-Fatigue change, which was observed in Study ALXN1210- PNH-301 in PNH 
patients. The power is 80% based on the standard deviation assumption of 13, which was 
observed in Study ACH471-101. 
9.3. Populations for Analyses  
The analysis populations are as follows: 
â€¢ Intent- to-treat (ITT) population: All randomized patients; data will be analyzed by [CONTACT_736122], even if the patient does not take the assigned treatment , does not receive the correct treatment, or does not 
comply with the protocol.  
â€¢ Per Protocol population: Intent- to-treat (ITT) patients who do not have protocol 
deviations expected to affect the primary efficacy endpoint (Week 12). Such protocol deviations will be prespecified in the statistical analysis plan prior to database lock.  
â€¢ Safety population: All patients who take at least one dose of danicopan or placebo. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005649] a similar number of patients (<5% 
difference), analyses will not be performed using the Per Protocol population. 
9.4. Statistical Analyses  
Categorical variables will be summarized with counts and percentages. Continuous variables will be summarized with univariate statistics (e.g., mean, median , standard error). 
Longitudinal summaries of efficacy and safety parameters will use pre- defined visit weeks. Visit 
windows around planned measurement times will be constructed, if appropriate, based on the midpoint between planned study visits. 
Efficacy and safety analysis results will be presented for both Treatment Periods of the study and 
by [CONTACT_1570] (danicopan and placebo). 
9.4.1. Patient Disposition and Demographic/Baseline Characteristics  
The number and percentages of patients will be provided for patient disposition for each study 
population. For enrolled patients who are not randomized, reasons for not being randomized will 
be listed and summarized. For patients who are randomized but do not receive study therapy, reasons for not receiving study therapy will be listed and summarized. For patients who are 
excluded from Per Protocol population, primary reasons of being excluded will be listed and 
summarized.  
Frequency distribution and summary statistics for demographic and baseline variables will be 
summarized. Key demographic and baseline variables to be summarized include geographic 
region, age, gender, race, height, weight, body mass index, RBC transfusion history [ADDRESS_1005650] dose date of danicopan or placebo during both treatment periods. 
Concomitant medication/therapy and background therapy verbatim terms will be coded using the 
latest version of the World Health Organization Drug Dictionary. The numbers and percentages 
of patients in each treatment group taking concomitant/background medications will be 
summarized by [CONTACT_736146].  
Note that an approved C5 inhibitor taken regularly with danicopan or placebo during double-
blind and open-label treatment periods is considered background therapy. The extent of exposure 
of approved C5 inhibitors taken during treatment periods will be presented separately from concomitant therapi[INVESTIGATOR_014].  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005651]- baseline measurements, and changes from baseline 
will be presented by [CONTACT_094]-defined visit for all continuous efficacy variables to be analyzed. 
[IP_ADDRESS]. Primary Efficacy Analysis 
The p rimary efficacy endpoint is change in hemoglobin at Week 12 relative to baseline (defined 
as the lowest Hgb value, between and including screening and Day 1) between danicopan and 
placebo. The longitudinal changes from baseline in hemoglobin will be analyzed using a mixed 
model for repeated measures (MMRM) ( Mallinckrodt, 2001, Mallinckrodt, 2004) which includes 
the fixed, categorical effects of treatment, study visit, and study visit by [CONTACT_736147], fixed covariate of baseline hemoglobin value and the 
stratification randomization indicator of transfusion history in the model. The Kenward-Roger 
approximation will be used to estimate denominator degrees of freedom.  
The primary objective is to evaluate the efficacy of danicopan as compared to placebo on change 
in hemoglobin after a 12-week of treatment. To address the impact of transfusion on hemoglobin 
values, for patients who are transfused on or after Week 8, the hemoglobin value collected at 
Week [ADDRESS_1005652] will be calculated  as the number of re-
randomized treatment group differences that are more extreme than the treatment group 
difference calculated under the actual randomization (ie, absolute value of re-randomized group 
difference larger than the absolute value of group di fference under the actual randomization) 
divided by [CONTACT_736148]-randomizations. 
With the relatively small sample size and short duration of blinded treatment (12 weeks), all 
efforts will be made to minimize missing Week [ADDRESS_1005653] under alternative missing data mechanism assumptions. The details of such analyses will be specified in the statistical analysis plan.  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 58 of 85 
Alexion Confidential  
 [IP_ADDRESS]. Secondary Efficacy Analysis 
The secondary efficacy endpoints are listed in Section 3. The secondary efficacy analysis will be 
conducted on the ITT population. 
Key secondary efficacy endpoints, in order of importance, are described below. Hierarchical 
fixed sequence test proced ure is utilized to determine the statistical significance at two -sided 
level of 0.05 for each endpoint sequentially. 
1. Difference in proportion of patients with Hgb increase of â‰¥  2 g/dL at Week 12 in the 
absence of transfusions 
2. Difference in proportion of patients with RBC transfusion avoidance between danicopan and placebo groups during the 12 weeks of treatment 
3. Difference in changes from baseline in FACIT -Fatigue scores between danicopan and 
placebo groups at Week 12. 
4. Difference in changes from baseline in absolute reticulocyte counts between danicopan and placebo groups at Week 12. 
For the parameter of proportions such as patients with Hgb increase of â‰¥  2 g/dL at Week 12 in 
the absence of transfusions (defined as achie ving â‰¥ 2 g/dL increase in Hgb from baseline to 
Week 12 and remaining transfusion free during 12-week Treatment Period 1), patients achieving 
transfusion avoidance and Hgb normalization at Week 12, the Cochrane- Mantel -Haenszel test 
will be used to compare between danicopan and placebo arms.  
For the changes in RBC transfusion units/instances from 12 weeks prior to initiation of treatment to 12-week Treatment Period 1, an analysis of covariance (ANCOVA) model including 
treatment arms and transfusion units/inst ances from [ADDRESS_1005654] procedure calls for the current hypothesis to be rejected; that 
is, if the p -value for test statistic is < 0.05, then proceed to test the significance of the next 
hypothesis from the key secondary endpoints listed above by [CONTACT_396052]. The sequential testing  process will be stopped when the hypothesis cannot be rejected. 
Results based on various statistical procedures used to analyze data for the remaining secondary efficacy and exploratory endpoints will be descriptive as follows: 
â€¢ Number and proportion of pa tients with hemoglobin stabilization during the last 
12 weeks of treatment, for  patients receiving 24 weeks of danicopan treatment. 
Hemoglobin stabilization is defined as avoidance of no more than a 1.0 g/dL decrease in Hgb levels at Week 24 from Week 12. 
â€¢ Change in RBC transfusion units/instances from 24 weeks prior to initiation of treatment to the 24 -week treatment period for patients receiving 24 weeks of 
danicopan treatment. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 59 of 85 
Alexion Confidential  
 â€¢ Proportion of patients with Hgb increase of â‰¥ 2 g/dL at Week 24 in the absence of 
transfusions, proportion of patients with transfusion avoidance through 24 weeks treatment period and proportion of patients with hemoglobin normalization at Week 24  
â€¢ Change in FACIT-Fatigue, absolute reticulocyte count, total and direct bilirubin, LDH and other PNH- related biomarkers relative to baseline (Day 1) for patients 
receiving 24 weeks of danicopan treatment. 
â€¢ Change from baseline in PNH RBC clone size, C3 fragment deposition on PNH RBCs, measures of alternate pathway and classical pathway activi ty, Bb, C3, and FD 
levels at Week 12 and Week 24. 
â€¢ Change from baseline in exploratory PRO and QoL endpoints at Week [ADDRESS_1005655] version of the Medical Dictionary for Regulatory Activities  (MedDRA). Reports will be provided to the medical monitor for approval of the coded 
terms after the database is clean, prior to database lock. Treatment -emergent adverse events (i.e., 
those adverse events that newly occur or worsen in severity after the first dose of the study drug will be summarized by [CONTACT_6657]. Tabulated listing of patients with 
SAEs and those who discontinue from the study due to an adverse event will be provided. 
Incidence of clinical laboratory abnormaliti es Grade 3 and above (based on version 5.0 of the 
National Cancer Institute Common Terminology Criteria for Adverse Events [CTCAE]) will be 
summarized. For laboratory tests with CTCAE toxicity grades available, laboratory abnormalities will be summarized b y worst treatment emergent grade. Any laboratory adverse 
event will also be classified by [CONTACT_736149].  
Shift tables will be provided for liver function test results and other selected laboratory test 
results based on CTCAE grades. In addition, shift tables based on multiple of ULN will also be 
produced for liver function test measurements.  
Data on vital signs and ECGs will be examined through subject listings and by [CONTACT_736150].  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 60 of 85 
Alexion Confidential  
 Other exploratory techniques (eg, graphic presentations), may also be used to facilitate clinical 
interpretations of the safety results.  
9.4.5. Analyses of Pharmacokinetics (PK) and Pharmacodynamic s (PD) 
Individual plasma concentration data for all patients who receive at least 1 dose of study drug (ie, danicopan) and who have evaluable PK data will be included in the PK analysis for danicopan. 
Descriptive statistics will be calculated for plasma concentration data at each sampling time, as 
appropriate. Population-PK modeling will be conducted using data from this study and/or in combination with data from other studies. 
PD analyses will be performed for all patients who receive at least [ADDRESS_1005656] dose PD data. Descriptive statistics will be presented for all danicopan PD endpoints at each sampling time. The PD effects of ALXN2040 administered 
orally will be evaluated by [CONTACT_736151], as appropriate. Assessments of danicopan PK-PD relationships may be explored using data from this study or in combination with data from other studies.  
9.5. Interim An alyses 
An interim analysis may be conducted at the discretion of the study sponsor (based on enrollment progression) when approximately 75% of patients have been randomly assigned to 
study treatment and have had the opportunity to complete the 12- week Trea tment Period 1 
(information fraction = 0.75). The purpose of the interim analysis is to evaluate the study for 
stoppi[INVESTIGATOR_681807]. If conducted, the primary endpoint of change in Hgb levels at Week 
12, as well as the key secondary endpoints will be evaluated using the alpha-spending methods 
specified below to control family -wise error rate.  
â€¢ The evaluation of primary endpoint at interim analysis will be using the gamma family alpha -spending function ( Hwang, 1990) with parameter -4. 
â€¢ The evaluation of key secondary endpoints at interim analysis will be using the gamma family alpha -spending function with parameter 1. 
Due to the hierarchical nature of primary and key secondary endpoints, and proper alpha-spending function used to control error rate at one -sided 0.025 level for each endpoint, the 
overall family -wise error rate is controlled at one-sided 0.025 level across primary and key 
secondary endpoints among interim and final analyses ( Glimm, 2010, Tamh ane, 2010). 
The recommendation of stoppi[INVESTIGATOR_736093]-controlled Treatment Period 1 for efficacy can be made only if, at a minimum, the primary endpoint of change in Hgb levels at 
Week 12 and the key secondary endpoints of proportion of patients with Hgb increase â‰¥  2g/dL in 
the absence of transfusion and proportion of patients with transfusion avoidance through 12week 
Treatment Period 1 meet the prespecified significance level. If the interim analysis is conducted 
with the timing and alpha-spending methods specified above, there is minimal change to the 
overall power for the primary endpoint, about 2-4% overall power decrease for the transfusion avoidance endpoint, and about 2-4% overall power decrease for the FACIT- Fatigue endpoint. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 61 of 85 
Alexion Confidential  
 The sponsor will decide whether to perform the interim analysis based on enrollment 
progression. If full enrollment is already completed or close to completion by [CONTACT_736152], the study will go directly to full analysis without an interim analysis.  
The interim analysis will be conducted under the auspi[INVESTIGATOR_736094]. The final decision to stop the study enrollment and placebo-controlled Treatment Period 1 for efficacy will be at the recommendation of the DMC. If such decision is made, the study may be modified to 
allow patients in the placebo arm to receive danicopan. The DMC review of the data will be 
independent of the Sponsor as the Sponsor will remain blinded. Details of the DMCâ€™s responsibilities and logistics will be outlined in the DMC charter before the dosing of the first patient.  
9.6. Staged Population PK/PD Analysis 
The staged population PK/PD analysis is planned prior to interim analysis, as well as prior to database lock. Pharmacodynamics will include AP activity, Bb, FD, C3, CP activity, and free C5.  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 62 of 85 
Alexion Confidential  
 10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1. Appendix  1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1. Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
â€¢ Ethical principles derived from international guidelines including the Declaration of 
Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines  
â€¢ Applicable ICH Good Clinical Practice (GCP) Guidelines  
â€¢ Applicable laws and regulations 
â€¢ The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (e.g., advertisements) must be submitted to an IRB/IEC by [CONTACT_22843]/IEC before the study is initiated. 
â€¢ Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study patients. 
â€¢ The Investigator will be responsible for the following: 
â€¢ Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC 
â€¢ Notifying the IRB/IEC of SAEs or other significant safety findings as required by [CONTACT_1744]/IEC procedures 
â€¢ Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations  
10.1.2. Financial Disclosure  
Investigators and sub-Investigators will provide the sponsor with sufficient, accurate financial information as requested to allow the sponsor to submi t complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completio n of the study. 
10.1.3. Informed Consent Process  
The Investigator or his/her representative will explain the nature of the study to the patient or his/her legally authorized representative and will review the informed consent and answer any 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 63 of 85 
Alexion Confidential  
 questions regarding the study. No study assessments or procedures will be performed until all the 
patientâ€™s questions have been answered and the patient has signed the ICF. 
Patients must be informed that their participation is voluntary. Patients or their legally authorized 
representative will be required to sign (written or electronic) a statement of informed consent that 
meets the requirements of [ADDRESS_1005657] (HIPAA) requirements, where applicable, and the IRB/IEC or study center. 
The medical record must include a statement that written or electronic informed consent was 
obtained before the patient was enrolled in the study and the date the consent was obtained. The authorized person obtaining the informed consent must also sign (written or electronic) the ICF. 
If the ICF is revised, patients must be re-consented (written or electronic) to the most current 
version of the ICF during their active participation in the study. 
A hard or digital copy of the ICF must be provided to the patient or the patientâ€™s legally 
authorized representative.  
A patient who is rescreened is required to sign another ICF. 
10.1.4. Data Protection 
Patients will be assigned a unique identifier by [CONTACT_456]. Any patient records or datasets that 
are transferred to the sponsor will contain the identifier only; patient names or any information 
which would make the patient identifiable will not be transferred.  
The patient must be informed that his/her personal study- related d ata will be used by [CONTACT_135711]. The level of disclosure must also be explained to the patient.  
The patient must be informed that his/her medical records may be examined by [CONTACT_384303], by [CONTACT_99473]/IEC members, and by [CONTACT_6668]. 
Alexion as a data controller has implemented privacy and security controls designed to help 
protect patient personal data, including information security controls, firewalls, incident 
detection, secure transfer measures, etc.  
In the event of any accidental or unlawful destruction, loss, alteration, unauthorized disclosure 
of, or access to, personal data (â€œbreachâ€), the controller has implemented procedures and 
measures to promptly address and mitigate any risk to the data subject. In the event of a breach, the controller will notify the appropriate regulatory authorities and/or the data subject in accordance with applicable dat a protection law.  
10.1.5. Dissemination of Clinical Study Data 
Company-sponsored study information and tabular study data will be posted on the US National Institutes of Health's website ( www.ClinicalTrials.gov ) and/or other publicly- accessible sites as 
required by [CONTACT_736153]. 
All information contained in this protocol and the study results are considered to be confidential. 
The Investigator agrees to use this information for purposes of conducting this study. It is 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005658], therefore, be sent to the Sponsor 60 days before 
submission for publication. 
10.1.6. Data Quality Assurance 
All patient data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (e.g., laboratory data). The Investigator is 
responsible for verifying that data entries are accurate and correct by [CONTACT_1189]. 
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
The Investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents. 
Monitoring details describing strategy, methods, responsibilities and requirements, including 
handling of noncompliance issues and monitoring techniques (central, remote, or on- site 
monitoring) are provided in the Medical Monitoring, Safety Monitoring and Global Monitoring Plans.  
The sponsor or designee is responsible for the data management of this study including quality checking of the data.  
The sponsor assumes accountability for actions delegated to other individuals (e.g., Contract Research Organizations).  
Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by [CONTACT_1191], complete, and verifiable from source documents; that the safety and rights of patients are being protected; and that the study is being 
conducted in accordance with the currently approved protocol and any other study agreements, 
ICH GCP, and all applicable regulatory requirements. 
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_13177] 2 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the sponsor. No records may be transferred to another location or party without written notification to the sponsor. 
10.1.7. Source Documents  
Source documents provide evidence for the existence of the patient and substantiate the integrity 
of the data collected. Source documents are filed at the Investigatorâ€™s site.  
Data entered in the CRF that are transcribed  from source documents must be consistent with the 
source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be ava ilable.  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005659] been collected.  
The Investigator may initiate study- site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_174277]:  
â€¢ Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines 
â€¢ Inadequate recruitment of patients by [CONTACT_737] 
â€¢ Discontinuation of further study intervention development 
10.1.9. Publication Pol icy 
All information contained in this protocol and the study results are considered to be confidential. The Investigator agrees to use this information for purposes of conducting this study. It is understood that the Sponsor may use data derived from this study for the purpose of research and 
development. The data may be disclosed by [CONTACT_736154], the FDA, other 
government agencies, or foreign drug regulatory authorities, or to the public. No publication of study design or results is permitted without specific approval by [CONTACT_1034]. To gain approval, a 
copy of the manuscript for review must, therefore, be sent to the Sponsor 60 days before 
submission for publication. 
It is the intent of the Sponsor. to present the results of this study at future scientific meetings. 
Additionally, it is the intent of the Sponsor to publish the results of this study in leading scientific 
journals. The Investigator of each investigative site will be invited to be an author in conjunction with the Investigator(s) from the Sponsor. The Sponsor will determine additional authors. Presentations and manuscripts will be provided and agreed to by [CONTACT_736155] 
10.2. Appendix  2: Clinical Laboratory Tests  
The tests detailed i n Table [ADDRESS_1005660] document their review of each 
laboratory report. 
 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 66 of 85 
Alexion Confidential  
 Table 7: Protocol- Required Laboratory Assessments  
Hematology  Chemistry  Urinalysis  Other Assessments1 
Complete blood count 
(CBC), including:  
Red blood cell (RBC) 
count  
White blood cell (WBC) 
count  
WBC differential 
(absolute and percent):  
- neutrophils  
- lymphocytes  
- monocytes  
- eosinophils  
- basophils  
Hematocrit (Hct)  
Hemoglobin (Hgb)  
Mean corpuscular volume (MCV)  
Mean corpuscular hemoglobin (MCH)  
Mean corpuscular hemoglobin concentration (MCHC)  
Mean platelet volume (MPV)  
Platelet count Red cell distribution 
width (RDW)  
Reticulocyte count 
(absolute and percent)  Alanine aminotransferase 
(ALT) 
Albumin  
Alkaline phosphatase  
Aspartate aminotransferase (AST)  
Bicarbonate (HCO
3) 
Bilirubin (fractionated)2 
Blood urea nitrogen 
(BUN)  
Calcium  
Calculated eGFR3 
Chloride  
C-reactive protein (CRP)  
Creatine kinase4 
Creatinine  
Gamma -glutamyl 
transferase (GGT) Glucose
5 
Lactate dehydrogenase Lipid profile including:  
Cholesterol/HDL ratio  
High -density lipoprotein 
cholesterol (HDL -C) 
Low-density lipoprotein 
cholesterol (LDL -C) 
Non-HDL -C 
Total cholesterol  
Triglycerides  
Very low -density 
lipoprotein cholesterol (VLDL -C) 
Potassium  
Sodium  
Total protein  
Uric acid  Analysis including:  
Bilirubin  
Color  
Glucose  
Ketones  
Leukocytes  
Nitrite  
Occult blood  
pH 
Protein  
Specific gravity  
Urobilinogen  
Microscopic examination of sediment  
 Alternative pathway (AP) 
activity  
Bb 
C3 
C3 fragment deposition  
Classical pathway (CP) activity  
Free C5  
D-dimer  
Direct Coombs  
Factor D  
Free hemoglobin  
Haptoglobin  
PNH clone size 
PT/PTT/INR  
Urine pregnancy test
6 
Iron studies:  
-Serum ferritin  
-Serum iron  
-Transferrin saturation  
-TIBC  
-Total Iron Binding 
Capacity (TIBC)  
Serology:  
-HCV and HBV 
antibodies  
-HIV- 1 and HIV -2 
antibodies  
-UGT1A1 (Gilbertâ€™s)  
[ADDRESS_1005661] bilirubin levels are 
> ULN at Screening but ALT and AST are normal, test for Gilbertâ€™s syndrome.  
3 Provide estimated glomerular filtration rate (eGFR) based on CKD -EPI [INVESTIGATOR_144326] (2009) for patients 
â‰¥19 years of age and based on the â€œbedside Schwartzâ€ equation (2009) for patients <[ADDRESS_1005662] > ULN.  
5 If glucose is > ULN, reflexively test HbA1c. 
[ADDRESS_1005663].  
 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 67 of 85 
Alexion Confidential  
 10.3. Appendix  3: Adverse Events: Definitions and Procedures  
for Recording, Evaluating, Follow -up, and Reporting  
10.3.1. Definitions  
Adverse events (AEs) must be assessed for the investigational product(s) in this study. An 
investigational product is defined as a pharmaceutical form of an active ingredient or placebo 
being tested or used as a reference in the study, whether blinded or unblinded. The term â€œadverse 
eventâ€ is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can arise with any use of the drug (e.g., 
off-label use, use in combination with another drug) and with any route of administration, 
formulation, or dose, including an overdose. 
Medical occurrences, including pregnancies, that begin before the start of study intervention but 
after obtaining informed consent will be recorded as a pre- treatment AE. While pregnancy itself 
is not considered an AE, for the purposes of safety monitoring, a pregnancy occurring after 
signing the ICF should be reported on the pregnancy forms and sent to Alexion Global Drug Safety (  or fax ). 
A treatment -emer
 gent adverse event (TEAE) is defined as an AE that emerges during treat ment, 
having been absent prior to treatment, or worsens relative to the pretreatment state. In this study, 
any AE first assessed after receipt of the first dose of danicopan until [ADDRESS_1005664] dose 
of study drug will be considered treatment- emerg ent, as defined in Section 10.3.5. All TEAEs 
will be recorded and reported.  
An AE (including a TEAE) can be one or more of the following: 
â€¢ Any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug and does not imply any judgment about causality. 
â€¢ Any new disease or exacerbation of an existing disease. 
â€¢ Recurrence of an intermittent medical condition (e.g., headache) not present at baseline.  
â€¢ Any case of abuse of alcohol, illicit drugs, or prescription drugs; abuse of study drug(s) or protocol-specified drug(s); addiction. 
â€¢ A pregnancy that occurs or becomes confirmed during a clinical study (see Section  1.2).  
â€¢ Laboratory test or other clinical test (e.g., ECG or X- ray) with a clinically significant 
abnormality (as define d below).  
â€¢ An effect of the study drug, including comparator. 
â€¢ Any dose of medication (study drug or other concomitant medication) that is taken at a dose higher than the prescribed dose (i.e., an overdose). Overdose should be reported as an AE whether or no t it is associated with any symptoms or signs. 

ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 68 of 85 
Alexion Confidential  
 The following are not considered to be AEs: 
â€¢ Medical or surgical procedures (e.g., surgery, endoscopi[INVESTIGATOR_014], tooth extraction, 
transfusion, etc.) - the condition which leads to the procedure is the AE; 
â€¢ Preexisting diseases or conditions or laboratory abnormalities present or detected prior to the screening evaluation that do not worsen; 
â€¢ Situations where an untoward medical occurrence has not occurred (e.g., 
hospi[INVESTIGATOR_63805], social an d/or convenience admissions, etc.) 
Clinically significant changes in objective findings (e.g., laboratory, ECG, physical examination) 
should be considered AEs only if they meet one or more of the following criteria: 
â€¢ Associated with accompanying symptoms;  
â€¢ Require medical/surgical intervention;  
â€¢ Lead to a change in study drug dosing or discontinuation from the study;  
â€¢ Lead to significant additional concomitant drug treatment, or other therapy;  
â€¢ Lead to any of the outcomes included in the definition of a serious adverse event;  
â€¢ Are considered clinically significant by [CONTACT_737]. 
Whenever possible, the etiology of the abnormal finding (rather than the abnormal finding itself) should be documented as the adverse event. Repeated additional tests and/or other evaluations required to establish the significance and etiology of an abnormal result should be obtained when clinically indicated.  
Any abnormal test result that is determined to be an error does not require reporting as an AE. 
Surgical procedures themselves are not AEs but are therapeutic measures for conditions that 
require surgery. The condition for which the surgery is required may be an AE, if it occurs or is 
detected during the study period. Planned surgical measures permitted by [CONTACT_736156] (if any) and the condition(s) leading to these measures are not AEs, if the condition(s) 
was (were) known before the start of the study treatment and documented in the participantâ€™s 
medical record. In the latter case, the condition should be reported as medical history.  
All participants who have AEs, whether considered to be associated with the use of the 
investigational product or not, must be monitored to determine the outcome of the event(s). The 
clinical course of the AE will be followed according to accepted standards of medical practice, even after the end of the period of observation, until a satisfactory explanation is found, or the Investigator considers it medically justifiable to terminate follow -up. 
10.3.2. Criteria for Assessing Seriousness  
All AEs must be evaluated as potential SAEs. If an event is not an AE per definition above, then 
it cannot be an SAE even if serious conditions are met. An SAE is any untoward medical occurrence that occurs at any dose and meets at least one of the following criteria:  
â€¢ Results in death  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 69 of 85 
Alexion Confidential  
 â€¢ Is life -threatening i.e., the participant was at immediate risk of death from the AE as it 
occurred. (This does not include an event that, had it occurred in a more severe form or was 
allowed to continue, might have caused death.)  
â€¢ Requires inpatient hospi[INVESTIGATOR_736109]. The 
following types of hospi[INVESTIGATOR_736110]: 
â€¢ Hospi[INVESTIGATOR_059](s) for planned (pre- scheduled) medical procedures known at the time 
of screening 
â€¢ Protocol- specific hospi[INVESTIGATOR_063]  
â€¢ Respi[INVESTIGATOR_4594]  
â€¢ Admission for the treatment of pre-existing condition (known at the time of screening) not associated with the development of a new AE or with the worsening of the pre -existing condition 
â€¢ Observation/same day/ambulatory procedure 
â€¢ Is a persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions 
â€¢ Is a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug) 
â€¢ Is an important medical event or reaction  
10.3.3. Documentation and Reporting of Adverse Events 
AEs, including TEAEs, may be reported by a participant or his/her representative, or to the Investigator elicited by [CONTACT_736157] a participant. All AEs will be assessed by [CONTACT_736158](s). For each AE, the Investigator will evaluate and report the date of 
onset and resolution, outcome, severity, relationship to study treatment(s), action taken, additional treatments required to manage the event, and determination of seriousness. All 
identified AEs occurring during the study and follow-up period must be fully recorded and 
described on the appropriate CRF page. The AE should be reported in standard medical terminology. Whenever possible, the AE should be evaluated and reported as a diagnosis, rather 
than as individual signs or symptoms. A cluster of signs and symptoms that results from a single 
cause should be reported as a single AE (e.g., fever, elevated WBC, cough, abnormal chest X-ray, etc. can all be reported as â€œpneumoniaâ€).  
If a definitive diagnosis is not possible, the individual symptoms and signs should be recorded. Documentation must be supported by [CONTACT_736159]â€™s medical record. The relationship to study drug or study procedures should be assessed using the definitions in Section  10.3.7. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 70 of 85 
Alexion Confidential  
 10.3.4. Treatment and Follow- Up of Adverse Events  
All AEs should be followed up (including obtaining relevant laboratory tests) until they have 
returned to baseline status or stabilized. If a clear explanati on is established, it should be 
recorded. Follow-up of AEs will continue through the last day on study (including the follow-up 
period) or until the events have resolved or stabilized to the satisfaction of the PI [INVESTIGATOR_537756] (or designee). The Sponsor may request that certain AEs be followed until resolution or 
stabilization.  
10.3.5. Timeframe for Collection of Adverse Events  
AEs include events that have appeared or worsened during the course of the clinical study. AEs 
may also include pre- or post -treatment complications that occur as a result of protocol- mandated 
procedures (e.g., invasive procedures, such as venipuncture, biopsy, etc.). 
Any AE (i.e., a new event or an exacerbation of a preexisting condition) with an onset date after 
the participant p rovides informed consent through the 30 days following the participantâ€™s last 
study drug dose will be recorded as an AE on the appropriate CRF page(s). 
All SAEs, regardless of cause or relationship, occurring within [ADDRESS_1005665] day on study or until the event has resolved or 
stabilized to the satisfaction of the PI [INVESTIGATOR_117404] (or designee). Investigators are 
not obligated to actively seek out SAEs beyond the follow-up period. However, if the PI (or 
designee) learns of an SAE occurring after completion of the final follow-up visit, and the SAE is deemed by [CONTACT_978] (or designee) to be related to the study drug (s), the PI (or designee) should 
promptly document and report the event to Alexion Global Drug Safety 
(  or fax )
 . 
10.3.6. Sev erity and Grading of Adverse Events  
The PI (or designee) should determine the severity of the AE based on the overall clinical 
importance or significance of the finding for that individual participant. If a lab abnormality is 
deemed to be clinically significant, it should be reported as an AE and the AE grade reported should correspond to the grade of the lab abnormality on the CTCAE grading scale. 
10.3.7. Assessment of Causality  
The Investigator must assess the likelihood that the study drug caused or contributed to each AE, 
and document this assessment assigning one of the binary criteria to each AE: 
âˆ’ Not related: There is no reasonable possibility the study intervention caused 
the adverse event.  
ï‚§ The adverse event has a more likely alternative etiology; it may be due to underlying or concurrent illness, complications, concurrent treatments, or effects of another concurrent drug.  
ï‚§ The event does not follow a reasonable temporal relationship to admin istration of the study intervention. 
âˆ’ Related: There is a reasonable possibility the study intervention caused the adverse event.  

ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 71 of 85 
Alexion Confidential  
 ï‚§ The adverse event has a temporal relationship to the administration of the 
study intervention. 
ï‚§ The event does not have a likely alternative etiology.  
ï‚§ The event corresponds with the known pharmaceutical profile of the study intervention 
ï‚§ There is improvement on discontinuation and/or reappearance on rechallenge  
For the purposes of determining expedited reporting status to Health Authorities, Sponsor 
considers the assessments of â€˜unrelatedâ€™ and â€˜unlikelyâ€™ as unrelated to study drug and â€˜possibleâ€™, 
â€˜probableâ€™, and â€˜definiteâ€™ as related to study drug. 
In addition, for any analyses of AE data in which only two categories of â€˜relatedâ€™ and â€˜unrelatedâ€™ 
are used, the assessments of â€˜unrelatedâ€™ and â€˜unlikelyâ€™ will be combined into the category of 
â€˜unrelatedâ€™, and the assessments of â€˜possibleâ€™ and â€˜probableâ€™ and â€˜definiteâ€™ will be combined into the category of â€˜relatedâ€™.  
10.3.8. Pregnancy  
Any pregnancy, including in a female partner of a male participant, that occurs or becomes confirmed during a clinical study (time frames outlined in Section 1.2) must be reported to Alexion Global Drug Safety (GDS) within [ADDRESS_1005666] knowledge of the pregnancy. The 
report should be provided on the Pregnancy/Breastfeeding Outcome form. While pregnancy 
itself is not considered an AE, for the purposes of safety monitoring, it should be reported to Alexion GDS on the pregnancy forms. 
All pregnancies temporally related to study drug should be followed and discussed with the 
medical monitor as follows: 
â€¢ The Investigator will follow up with the participant or the par ticipantâ€™s female partner 
approximately every 3 months throughout the pregnancy and report to Alexion GDS 
using the Pregnancy/Breastfeeding Outcome form. A follow up on the status of the 
baby [CONTACT_736160] 3 months of age of the baby. 
â€¢ The Investigat or will report any information on the status of the pregnancy including 
outcome to Alexion GDS (  or fax   
â€¢ Any termination of pregnancy will be reported, regardless of fetal status (i.e., pr
esence or absence of anomalies) or indication for the procedure. 
Any SAEs related to the pregnancy (see below), or occurring during the participantâ€™s pregnancy, or after delivery, must be documented and reported to Alexion GDS both el ectronically via the 
Rave Safety Gateway and via the Pregnancy/Breastfeeding Outcome form. SAEs occurring in 
the child (e.g., congenital anomalies or other conditions present at birth, whether genetically 
inherited or occurring in utero) must also be reported to Alexion GDS both electronically via the Rave Safety Gateway and via the Pregnancy/Breastfeeding Outcome form.  
â€¢ Reportable SAEs associated with pregnancy include, but are not limited to: 
â€¢ Pregnancy losses (e.g., spontaneous abortion, late fetal death, elective termination)  
â€¢ Life-threatening developments (e.g., placental abruption, fetal distress) 

ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 72 of 85 
Alexion Confidential  
 â€¢ Congenital anomalies 
â€¢ Neonatal or maternal death, or  
â€¢ Any event resulting in maternal or neonatal hospi[INVESTIGATOR_059]/prolonged hospi[INVESTIGATOR_059]. 
10.3.9. Reporting Serious Adv erse Events and Pregnancies  
The Sponsor has requirements for the expedited reporting of safety events meeting specific 
requirements to worldwide regulatory authorities, and therefore, must be notified immediately 
regarding the occurrence of any SAE and/or pregnancy that occurs during the study (time frames 
outlined in Section 1.2).  
For SAEs and/or pregnancies occurring during the study, the Investigator or delegate will enter all relevant information in the eCRF.  
All SAEs that occur during the course of the study, whether or not causally related to the investigational product, must be entered into the eCRF immediately (within 24 hours of the 
investigator becoming aware of the event) and electronically transmitted to Alexion GDS via the 
Rave Safety Gateway.  
In addition, the Investigator must: 
â€¢ Report all site -specific SAEs to the relevant Institutional Review Board (IRB) / 
Independent Ethics Com mittee (IEC) within the timeframe specified by [CONTACT_1201] / IEC 
as per local procedures/policies.  
â€¢ If the subject is an active participant in the study: 
â€¢ Enter follow-up information in the eCRF until the SAE has resolved, or, in the case of 
permanent impairment, until stabilized.  
â€¢ Ensure that the causality assessment for all SAEs is entered in the eCRF.  
â€¢ If the patient is no longer participating in the study, report the follow-up information to the sponsor. 
In the case of a medical emergency, the Medical Monitor must be contact[INVESTIGATOR_530].  
10.3.10. Investigator Reporting Requirements for S[LOCATION_003]Rs  
The Sponsor is responsible for ensuring that Investigators and central ECs/IRBs are notified of 
all AEs that are serious, unexpected and considered related, probably related, or possibly rel ated 
to the investigational product. A CRO may be designated to perform this notification. This 
notification will be in the form of a MedWatch/CIOMS report. The PI [INVESTIGATOR_736111]. Upon receiving such notices, the PI [INVESTIGATOR_736112]. The Sponsor, Investigator, and EC or IRB will determine if the informed consent requires revision. The PI [INVESTIGATOR_736113]. 
10.3.11. Concomitant/Background Medication Assessments  
Details of all concomitant/background medication use, including all medications administered 
for the treatment of AEs, will be recorded in the participantâ€™s CRF at each study visit. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 73 of 85 
Alexion Confidential  
 10.3.12. Monitoring Participant Safety 
The safety of p articipants will be monitored by [CONTACT_736161]â€™s medical monitor 
(or designee) on an ongoing basis while participants are receiving the study drug.  
10.3.13. Removal of Participants from the Study or Study Drug 
A participant is free to withdraw from the study at any time without jeopardizing future medical 
care. The PI (or designee) may decide, for reasons of medical prudence or participant 
noncompliance, to discontinue dosing in a participant. The PI [INVESTIGATOR_736114]. In either case, whenever possible, the Medical Monitor should be notified immediately, and if possible, before dosing is terminated. 
If dosing is to be terminated, it may be done so immediately, or a taper can be implemented as 
described in protocol, whichever is considered to be in the best interest of the participant. When dosing is terminated, study participation is not necessarily immediately terminated. Instead, 
whenever possible, the participant should complete all activities in the taper and follow-up 
periods (if tapered) or in the follow-up period (if discontinued immediately), as described in Appendix 1. 
Reasons for participant withdrawal include (but are not limited to): 
â€¢ One or more of the stoppi[INVESTIGATOR_736115] 
â€¢ Intercurrent illness that would, in the judgment of the Investigator, affect assessments 
of clinical status to a sign ificant degree  
â€¢ Unacceptable toxicity (including a clinically significant laboratory abnormality) 
necessitating discontinuation of study or that, in the judgment of the Investigator, compromises the ability to continue study-specific procedures, or it is considered not to be in the participantâ€™s best interest to continue the study  
â€¢ Participant request to discontinue for any reason 
â€¢ A female participant becomes pregnant or wishes to become pregnant 
â€¢ Participant noncompliance 
â€¢ Discontinuation of the study at the request of the Sponsor, regulatory agency, or Ethics Committee or IRB  
â€¢ Any other condition or circumstance that would jeopardize the welfare of the participant if s/he were to continue in the study 
The reason for any participantâ€™s discontinuation and the da te of withdrawal will be recorded in 
the participantâ€™s CRF. The participantâ€™s CRF, which will be completed up to the point of withdrawal, will be retained for the sponsor. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 74 of 85 
Alexion Confidential  
 10.4. Appendix  4: Contraception Guidance and Collection of Pregna ncy 
Information  
Definitions:  
Woman of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile (see below).  
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered. 
Women in the following categories are not considered WOCBP 
1. Premenarchal  
2. Premenopausal female with [ADDRESS_1005667] 6  months prior to dosing: 
â€¢ Documented hysterectomy  
â€¢ Documented bilateral salpi[INVESTIGATOR_8936]-oophorectomy  
â€¢ Documented bilateral oophorectomy 
For individuals with permanent infertility due to an alternate medical cause other than the above, 
(e.g., Mullerian agenesis, androgen insensitivity), Investigator discretion should be applied to determining study entry. 
Note: Documentation must come from the site personnelâ€™s: review of the patientâ€™s medical 
records.  
Postmenopausal female meeting both of the c riteria below: 
â€¢ A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.  
â€¢ A high follicle stimulating hormone (FSH) level in the postmenopausal range must be used to confirm a postmenopausal state. 
Females on HRT an d whose menopausal status is in doubt will be required to use one of the non-
estrogen hormonal contraception methods if they wish to continue their HRT during the study. 
Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status be fore 
study enrollment. 
Contraception Guidance: Patients on C5 inhibitor therapy should adhere to the 
contraception guidelines as per local country label requirements  
Contraception for Male Patients  
All non- sterile male patients must use highly effective or  acceptable methods of contraception 
with their partner(s) of childbearing potential from the first day of dosing (Day 1) through 90 days (a spermatogenesis cycle) after their last dose of study drug. 
Sterile is defined as having bilateral orchiectomy. Highly effective contraception for males is defined as any of the following:  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 75 of 85 
Alexion Confidential  
 â€¢ Vasectomy with confirmed medical assessment of surgical success  
â€¢ Condom plus use of one of the following by [CONTACT_94167](s) of child-bearing potential: 
â€¢ Oral, intravaginal, or transdermal combined (estrogen and progestogen containing) 
hormonal contraception associated with inhibition of ovulation 
â€¢ Oral, injectable, or implantable progestogen-only hormonal contraception associated 
with inhibition of ovulation 
â€¢ Intrauterine device ( IUD) or intrauterine hormone- releasing system (IUS)  
â€¢ Bilateral tubal occlusion  
â€¢ Sexual abstinence, defined as refraining from heterosexual intercourse during the entire period from the first day of dosing (Day 1) through [ADDRESS_1005668] dose of study drug. Periodic abstinence (e.g., calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the clinical study and 
the preferred  and usual lifestyle of the patient. If a patient is usually not sexually 
active but becomes active, they, with their partner(s), must comply with the contraceptive requirements described in this section.  
Acceptable contraceptive methods include:  
â€¢ A combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods) 
Male patients must agree to refrain from sperm donation while enrolled in this study and for 90 days (a s permatogenesis cycle) after their last dose of study drug. 
Contraception for Female Patients  
Female patients of childbearing potential must use a  highly effective or acceptable method of 
contraception from the date of signing the informed consent until the specified duration after the last dose of their background C5 inhibitor as per the product labelling. 
Highly effective contraception for females is defined as any of the following: 
â€¢ Oral, intravaginal, or transdermal combined (estrogen and progestogen containing) 
hormonal contraception associated with inhibition of ovulation 
â€¢ Oral, injectable, or implantable progestogen-only hormonal contraception associated 
with inhibition of ovulation 
â€¢ IUD or IUS  
â€¢ Bilateral tubal occlusion  
â€¢ Vasectomized partner(s) with confirmed medical assessment of surgical success  
â€¢ Sterile partner(s) (bi -lateral orchiectomy)  
â€¢ Sexual abstinence, defined as completely refraining from heterosexual intercourse. Periodic abstinence (e.g., calendar, symptothermal, post-ovulation methods) is not an 
acceptable method of contraception. The reliability of sexual abstinence needs to be 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 76 of 85 
Alexion Confidential  
 evaluated in relation to the duration of the clinical study and the preferred and usual 
lifestyle of the patient. If a patient is usually not sexually active but becomes a ctive, 
they, with their partner(s), must comply with the contraceptive requirements 
described in this section. 
Acceptable contraceptive methods include:  
â€¢ A combination of male condom with either cap, diaphragm, or sponge with 
spermicide (double barrier met hods) 
Female patients of childbearing potential must have a negative urine pregnancy test in order to 
enter the study and must have urine pregnancy tests throughout the study at the intervals defined in the Schedule of Assessments. 
Female patients of non -childbearing potential need not employ a method of contraception. 
Collection of Pregnancy Information Any pregnancy, including female partner pregnancies of male patients, that occurs or becomes 
confirmed during a clinical study must be reported to the Sponsor (or designee) within one business day of first knowledge of the pregnancy, as described in Section 8.5.5. The report 
should be provided on the pregnancy form. While pregnancy itself is not considered an AE, for 
the purposes of tracking, it should be captured as an AE as well as reported on the pregnancy forms.  
All pregnancies temporally related to taking study drug should be followed and discussed with the medical monitor as follows: 
â€¢ The Investigator will follow up with the patient approximately every [ADDRESS_1005669] information on the status of the pregnancy. 
Generally, follow up will not be required for longer than 6-8 weeks beyond the 
estimated delivery date.  
â€¢ The Investigator will report any information on the status of the pregnancy to the Sponsor (or designee) using the pregnancy forms. 
â€¢ The final outcome of the pregnancy will be reported to the Sponsor (or designee) using the pregnancy forms. Any termination of pregnancy will be reported, regardless of fetal status (i.e., presence or absence of anomalies) or indication for the procedure. 
Any SAEs related to the pregnancy (see below), or occurring during the pregnancy, or after delivery, must be documented and reported to the Sponsor (or designee) on both the SAE Form 
and the pregnancy forms. SAEs occurring in the child (e.g., congenital anomalies or other 
conditions present at birth, whether genetically inherited or occurring in utero) must also be documented on both the SAE form and the pregnancy forms. 
Reportable SAEs associated with pregnancy include, but are not limited to: 
â€¢ Pregnancy losses (e.g., spontaneous abortion, late fetal death, elective termination)  
â€¢ Life-threatening developments (e.g., placental abruption, fetal distress) 
â€¢ Congenital anomalies 
â€¢ Neonatal or maternal death  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 77 of 85 
Alexion Confidential  
 â€¢ Any event resulting in maternal or neonatal hospi[INVESTIGATOR_059]/prolonged hospi[INVESTIGATOR_059]. 
10.5. Appendix  5: Genetics  
Subject to patient consent, a sample will also be collected at screening for potential genetic 
analysis.  Genetic analyses may be conducted if a patient does not respond to the investigative 
drug, to better understand a potential drug-r elated toxicity, or to further characterize the 
underlying disease. Genes which may be sequenced include (but are not limited to):  
â€¢ Complement component C3 
â€¢ Complement factor H -related proteins (CFHR1, CFHR3, CFHR4, CFHR5) 
â€¢ Complement factor B  
â€¢ Complement fact or D 
â€¢ Complement factor H  
â€¢ Complement factor I  
â€¢ Membrane co -factor protein (MCP/CD46) 
â€¢ Thrombomodulin (THBD) 
â€¢ CR1 
All genetic samples will be stored for a maximum of 3 years after completion of the clinical study report. During that time, samples may be retested if other mutations are discovered that may be associated with PNH. Patients may withdraw their consent for genetic testing and 
withdraw their samples from further genetic testing at any time by [CONTACT_736162]. Af ter the 3 -year storage period defined above, or once the 
sponsor is informed of withdrawal of consent for further analysis, the sample will be destroyed 
consistent with accepted laboratory standards and no further testing or analysis will be 
completed. Any data already generated from the sample may continue to be used for the purposes of this study and future research. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 78 of 85 
Alexion Confidential  
 10.6. Appendix  6: COVID- 19 Risk Assessment  
PNH can cause irreversible morbidity and even mortality, if untreated. As such, and due to the 
limited number of available treatment options, the benefit a participant may receive from joining 
an investigational study with a therapeutic treatment is potentially significant. Given that treatment for PNH does involve immunosuppression, there is a theoretical concern that the risk 
for infection may be higher than in participants not receiving immunosuppressants. However, 
there is no specific data to further inform this risk. The site Investigator will therefore balance the risk/benefit considerations in the study participant taking these factors into account.  
The potential risks identified and mitigation measures put in place in light of the COVID -19 
pandemic are provided in Table 8.  
Table  8: Potential Risks and Mitigation Measures due to COVID -19 
Risks Category  Summary of Data/  
Rationale for Risk  Mitigation Strategy  
Potential risks  
Potentially higher risk 
population for 
SARS -CoV -[ADDRESS_1005670] their risk for SARS -CoV -2 infection.  During the time that the 
COVID- 19 pandemic is active, 
Alexion will recommend that sites in a position to start the study and enroll participants follow the national and institutional guidances 
regarding prevention of 
SARS -CoV -2 infection.  
Additionally, during that time period, it is expected that Investigators and their staff will 
take all possible precautions in 
order to minimize a participantâ€™s potential exposure to SARS -CoV -[ADDRESS_1005671] the resourcing and capabilities to 
implement the study per 
protocol.  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 79 of 85 
Alexion Confidential  
 Table  8: Potential Risks and Mitigation Measures due to COVID -19 
Risks Category  Summary of Data/  
Rationale for Risk  Mitigation Strategy  
Data quality and 
integrity  Lack of availability of site personnel to perform 
study assessments and capture study specific data in 
a timely manner and to maintain adequate quality standards.  
Lack of availability of site personnel to ensure adequate and continuous chain of custody, storage conditions, and monitoring for investigational product and biological samples.  
Inability of study monitors and quality personnel to conduct in- person visits to exercise adequate 
oversight of study execution at investigational sites.  
Missing data (COVID -[ADDRESS_1005672] 
study visit schedules and increase missed visits 
and/or participant study discontinuations 
inadvertently resulting in missing data [eg, for 
protocol -specified procedures]). During the time that the 
COVID- [ADDRESS_1005673] clinical study- related activities.  
During this timeframe, participants eligibility as well as site capacity will be reviewed by [CONTACT_736163]. Each site is also 
evaluated for the capacity to 
perform remote monitoring visits  and remote source data 
verification.  
During the time that the COVID- 19 pandemic is active, 
it will be important to capture specific information in the eCRF that explains the reason the data is missing (eg, missed study visits or participant study 
disconti nuations due to 
COVID- 19). 
Abbreviations: C5 = complement protein 5; COVID- 19 = coronavirus disease 2019; eCRF  = electronic case report 
form; SARS -CoV -2 = severe acute respi[INVESTIGATOR_6507] 2.  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 80 of 85 
Alexion Confidential  
 10.7. Appendix  7: COVID -19 Vaccine Risk Assessment  
Following a review of the available COVID- 19 vaccine data (eg, [COMPANY_007]/BioNTech, Moderna, 
[COMPANY_008], [COMPANY_012]), it is unlikely that the immune response to a COVID-19 
vaccine (and therefore the efficacy of the vaccination) would be diminished with concomitant danicopan administration, based on danicopanâ€™s mechanism of action. There is currently no 
information available evaluating the safety and efficacy of COVID -[ADDRESS_1005674] in light of the COVID -19 
vaccination rollout are provided in Table 9: . 
Table  9: Potential Risk and Mitigation Measures due to COVID -19 Vaccination  
Risk Category  Summary of Data/Rationale for Risk  Mitigation Strategy  
Potential risk  
Data quality and 
integrity  Missing data due to appointments for COVID -[ADDRESS_1005675] study visit schedules and increase 
missed visits and/or participant study discontinuations, inadvertently resulting in 
missing data (eg, for protocol -specified 
procedures) . Capture specific information in the 
eCRF that explains the reason the 
data is missing (eg, missed study visits due to appointments for COVID- 19 vaccination or side 
effects of COVID -19 vaccine)  
Abbreviation: COVID -19 = coronavirus disease 2019.  
  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 81 of 85 
Alexion Confidential  
 10.8. Appendix  8: Abbreviations  
 
Abbreviation  Definition  
AE Adverse event  
ALP  Alkaline phosphatase  
ALT  Alanine transaminase  
ANCOVA  Analysis of covariance  
AP Alternative pathway (of complement)  
AST  Aspartate aminotransferase  
Bb Bb fragment of complement factor B  
C3 C3 complement protein  
C5 C5 complement protein  
C3G  C3 glomerulopathy  
CIOMS  Council for International Organizations of Medical Sciences  
CP Complement classical pathway  
CRF  Case report form  
CTCAE  National Cancer Institute Common Terminology Criteria for Adverse Events  
DMC  Data Monitoring Committee  
ECG  Electrocardiogram  
eCRF  electronic case report form  
eGFR  Estimated glomerular filtration rate  
EORTC  European Organization for Research and Treatment of Cancer  
EQ-5D-3L Three -level version of EuroQoL 5 Dimensions questionnaire  
EVH  Extravascular hemolysis  
FACIT -Fatigue  Functional Assessment of Chronic Illness Therapy -Fatigue scale (version 4.0)  
FB (Complement) Factor B  
FD (Complement) Factor D  
FSH  Follicle stimulating hormone  
GCP  Good Clinical Practice  
GGT  gamma -glutamyl transferase  
Hct Hematocrit  
HCV  Hepatitis C virus  
Hgb Hemoglobin  
HIPAA  Health Insurance Portability and Accountability Act of [ADDRESS_1005676]  
IRT Interactive response technology  
ITT Intent -to-treat 
IUD Intrauterine device  
IUS Intrauterine hormone -releasing system  
LDH  Lactate dehydrogenase  
LTE Long -Term extension  
MedDRA  Medical Dictionary for Regulatory Activities  
MMRM  Mixed model for repeated measures  
PD Pharmacodynamic(s)  
PK Pharmacokinetic(s)  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 82 of 85 
Alexion Confidential  
 Abbreviation  Definition  
PNH  Paroxysmal nocturnal hemoglobinuria  
pRBC  Packed red blood cells  
PRO  Patient -reported outcome  
PT Prothrombin time  
PTT Partial thromboplastin time  
QLQ -C30 Quality of Life Questionnaire -Core 30 Scale  
QoL Quality of life  
QRS  Group of electrocardiogram waves comprising the Q, R, and S waves  
QT Period (in milliseconds) from the beginning of the QRS complex until the end of the T wave  
QTcF  QT interval Fridericia Correction Formula  
RBC  Red blood cells  
RR Respi[INVESTIGATOR_736116] -emergent adverse event  
tid Three times per day  
ULN  Upper limit of normal  
WBC  White blood cell  
Wk Week  
VHA  Visit Healthcare Assessment  
  
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005677]. 2001;108(2):233-40. doi: 
10.1172/jci12023. 
2. Curran KJ, Kernan NA, Prockop SE, Scaradavou A, Small TN, Kobos R, et al. 
Paroxysmal nocturnal hemoglobinuria in pediatric patients. Pediatr Blood Cancer. 
2012;59(3):525-9. doi: 10.1002/pbc.[ZIP_CODE]. 
3. Debureaux P-E, Cacace F, Silva BGP, Barone F, Calado RT, Sicre de Fontbrune F, et al. 
Hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: 
application of a novel classification  to identify unmet clinical needs and future clinical 
goals. Blood. 2019;134(Supplement_1):3517-. doi: 10.1182/blood-2019-125917. 
4. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991;4(3):359-95. doi: 10.1128/cmr.4.3.359. 
5. Glimm E, Maurer W, Bretz F. Hierarchical testing of multiple endpoints in group-sequential trials. Stat Med. 2010;29(2):219-28. doi: 10.1002/sim.3748. 
6. Harder MJ, Kuhn N, Schrezenmeier H, HÃ¶chsmann B, von Zabern I, Weinstock C, et al. Incomplete inhibition by [CONTACT_151305]: mechanistic evidence for residual C5 activity 
during strong complement activation. Blood. 2017;129(8):970-80. doi: 10.1182/blood-
2016-08-732800. 
7. Hiemstra PS, Langeler E, Compi[INVESTIGATOR_3694] B, Keepers Y, Leijh PC, van den Barselaar  MT, et al. 
Complete and partial deficiencies of complement factor D in a Dutch family. J Clin Invest. 1989;84(6):1957-61. doi: 10.1172/jci114384. 
8. Hill A, Platts,P.J., Smith,A., Richards,S.J., Cullen,M.J., Hill,Q.A., Roman,E., and 
Hillmen,P. The incidence and prevalence of paroxysmal nocturnal haemoglobinuria 
(PNH) and survival of patients in Yorkshire. Br J Haematol. 2007;137:31. 
9. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal 
nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253-8. doi: 
10.1056/nejm199511093331904. 
10. Hwang IK, Shih WJ, De Cani JS. Group sequential designs using a family of type I error 
probability spending functions. Stat Med. 1990;9(12):1439-45. doi: 
10.1002/sim.[PHONE_15298]. 
11. Kobayakawa H, Miyata T, Inagi R, Shinzato T, Maeda K. Effects of excess factor D on 
early - and late-phase activation of the complement cascade. Nihon Jinzo Gakkai Shi. 
1992;34(1):103-6. 
12. Konar M, Granoff DM. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by [CONTACT_554472]. Blood. 2017;130(7):891-9. doi: 
10.1182/blood-2017-05-781450. 
13. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed- effects 
models. J Biopharm Stat. 2001;11(1- 2):9-21. doi: 10.1081/bip-100104194. 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) [ADDRESS_1005678] 
ANOVA. Clin Trials. 2004;1(6):477-89. doi: 10.1191/1740774504cn049oa. 
15. McKinley CE, Richards SJ, Munir T, Griffin M, Mitchell LD, Arnold L, et al. Extravascular hemolysis due to C3- loading in patients with PNH treated with 
eculizumab: Defining the clinical syndrome. Blood. 2017;130(Supplement 1):3471-. doi: 10.1182/blood.V130.Suppl_1.3471.3471. 
16. Miyata T, Inagi R, Oda O, Inoue I, Okada H, Miyama A, et al. Deterioration of immune complex solubilization activity of serum by [CONTACT_736164] D. Nephron. 1991;59(3):409-15. doi: 10.1159/000186600. 
17. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7):632-9. doi: 10.1056/NEJMoa1311084. 
18. Risitano AM, Notaro R, Marando L, Serio B, Ranaldi D, Seneca E, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal 
nocturnal hemoglobinuria patients treated by [CONTACT_151305]. Blood. 2009;113(17):4094-
100. doi: 10.1182/blood-2008-11-189944. 
19. Risitano AM, Roth A, Soret J, Friere C, de Fontbrune FS, Marano L, Rozenberg I, 
Milojevic J, End P, Nidamarthy PK, Junge G, De Latour RP. A new oral complement 
factor -b inhibitor normalizes hemoglobin in paroxysmal nocturnal hemoglobinuria 
patients with poor response to eculizumab, both as add-on and monotherapy. 46th Annual 
Meeting of the European Society for Blood and Marrow Transplantation (EBMT); [ADDRESS_1005679] - 1 September2020. 
20. Rondelli T, Risitano AM, Peffault de Latour R, Sica M, Peruzzi B, Ricci P, et al. 
Polymorphism of the complement receptor 1 gene correlates with the hematologic 
response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2014;99(2):262-6. doi: 10.3324/haematol.2013.090001. 
21. Schnabolk G, Coughlin B, Joseph K, Kunchithapautham K, Bandyopadhyay M, O'Quinn EC, et al. Local production of the alternative pathway component fact or B is sufficient to 
promote laser -induced choroidal neovascularization. Invest Ophthalmol Vis Sci. 
2015;56(3):1850-63. doi: 10.1167/iovs.14-[ZIP_CODE]. 
22. Schubert J, RÃ¶th A. Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease. Eur J Haematol. 2015;94(6):464-73. doi: 10.1111/ejh.[ZIP_CODE]. 
23. SociÃ© G, Caby -Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, et al. 
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypi[INVESTIGATOR_736117]: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297-310. 
doi: 10.1111/bjh.[ZIP_CODE]. 
24. Sprong T, Roos D, Weemaes C, Neeleman C, Geesing CL, Mollnes TE, et al. Deficient 
alternative complement pathway activation due to factor D deficiency by 2 novel 
ALXN2040  Alexion Pharmaceuticals, Inc.  
Protocol ALXN2040- PNH -301 Amendment 6.3 (US) 08  Aug 2022  
Page 85 of 85 
Alexion Confidential  
 mutations in the complement factor D gene in a family with meningococcal infections. 
Blood. 2006;107(12):4865-70. doi: 10.1182/blood-2005-07-2820. 
25. Tamhane AC, Mehta CR, Liu L. Testing a primary and a secondary endpoint in a group sequential design. Biometrics. 2010;66(4):1174-84. doi: 10.1111/j.1541-0420.2010.[ZIP_CODE].x. 
26. Volanakis JE, Narayana SV. Complement factor D, a novel serine protease. Protein Sci. 1996;5(4):553-64. doi: 10.1002/pro.[PHONE_15299]. 
27. Yuan X, Gavriilaki E, Thanassi JA, Yang G, Baines AC, Podos SD , et al. Small- molecule 
factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypi[INVESTIGATOR_151258]. Haematologica. 2017;102(3):466-75. doi: 10.3324/haematol.2016.153312. 
 